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There are over 100,000 patients on organ transplant waiting lists, creating a significant need to 
expand the donor pool. The heart is the most difficult organ to preserve ex vivo, with a short 
viable storage time of 4-6 hours, because damage to mitochondria during preservation can impair 
can be extended. Hydrogen sulfide (H2S) has been shown to reduce metabolism, increase 
preservation times, and enhance graft viability. We have developed gelatin microspheres under 
10 microns able to slowly release H2S and investigated different crosslinking concentrations to 
understand the time release profiles. These microspheres were then used to maintain H2S levels 
in cardiomyocyte cell cultures without decreasing cell viability. Histological samples from 20 
cold-stored rat hearts in various experimental treatments show H2S-releasing microspheres offer 
protection against preservation injury comparable to the current clinical standard, University of 
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Nearly 110,000 people in the United States are on the organ transplant waiting 
list, yet only 77 actually receive organ transplants daily. Organ transplantation today is 
hampered not only by the shortage of available organs, but also by current methods of 
organ storage, which provide a limited timeframe of organ viability. Currently, the 
viability of hearts is limited to a mere four to six hours, creating significant restrictions 
and logistical problems with regard to the timing of organ transportation. The duration of 
hypothermic storage and the perfusion techniques utilized to protect organs from 
ischemia-reperfusion (I/R) injury are important. Preservation-induced injury is a major 
contributing factor to early graft dysfunction in recipients. By extending the limits of 
organ storage, it would be possible to broaden the geographical radius to which a donated 
organ could be delivered, and ultimately widen the pool of potential organ transplantation 
recipients. 
The most common method used for organ storage today is cold storage. Standard 
methods for static cold storage involve the use of low temperatures and the University of 
Wisconsin (UW) solution. The components of the UW solution help reduce swelling of 
the organ, while hypothermic preservation reduces metabolism and therefore harmful 
metabolic waste. Additionally, the solution provides rapid cooling as well as a sterile 
environment. However, while the UW solution lowers aerobic metabolism, anaerobic 
metabolism persists. The oxygen free radicals subsequently generated lead to I/R injury, 
inflammation, tissue damage, and cell death. Additives to UW solution, such as 
perfluorocarbons, improve the preservative capabilities of the solution through a variety 




to static cold storage solutions, heart storage time has yet to clinically exceed 8 hours. 
Methods other than static cold storage include hypothermic machine perfusion, used 
mainly for kidneys, and normothermic perfusion, which is performed at 37°C. Both are 
promising, but limited in their applicability because they require relatively large pieces of 
equipment to maintain storage conditions. In short, existing techniques for organ storage 
are inadequate, and have limited viability time and high risks of injury and inflammation. 
These obstacles create the need for a better means of organ storage. 
This research study focuses on utilizing a promising chemical, hydrogen sulfide 
(H2S), to extend and improve upon the current organ storage methods. Recent research 
has shown that H2S can induce a state of hibernation, which has been proven to protect 
hearts in storage from I/R injury. However, as will be discussed in the sections to follow, 
H2S does have some inherent problems. For example, H2S cannot be used as a simple 
additive to the original storage solutions, as an estimated one-third of the molecules are 
completely unused and escape in the form of a deadly gas. In addition, H2S may be 
consumed by the heart cells themselves, which also compromises its effectiveness for 
storage. 
In order to address these issues, we propose the use of gelatin microspheres that 
will allow for continuous delivery of H2S to the heart and potentially improve both the 
practicality of using H2S for organ preservation and the protective effects requiring the 
presence of H2S. This hydrogel delivery system utilizes polymer networks that can 
provide a protective haven for many drugs that are normally degraded in circulation. 




biodegradability, and biologically recognizable moieties, and have previously been used 
in cardiac drug delivery applications with no side effects.  
Objectives 
The goal of this research study was to explore a novel preservation method 
utilizing H2S to induce a protective state of hibernation against I/R injury. Although H2S 
has been shown to reduce metabolic rates, ATP consumption, and the production of 
reactive oxidative species (ROS), research has not adequately addressed how long hearts 
should be exposed to H2S for optimal protection. It was hypothesized that continuous 
release of H2S in the preservation solution will result in better protection of the heart 
during cold storage. Such continuous release may be achieved by gelatin hydrogel 
microspheres loaded with sodium hydrogen sulfide (NaHS), an H2S donor.  
The global hypothesis was that H2S-loaded gelatin hydrogel microspheres will 
deliver H2S throughout the heart in a continuous, controlled manner to enhance protective 
effects associated with H2S, including K-ATP channel opening, ROS scavenging, and 
hibernation, which will prolong heart viability, reduce I/R injury, and be practical for 
clinical implementation. 
The overall goal was to develop a novel method for heart preservation that would 
not only extend heart viability in storage, but would 
transport methods. We hypothesized that compared to existing methods of storage, 
controlled delivery of H2S will improve heart viability as determined by metabolic 
activity, viability assays, and ATP assay and caspase-3 assays.  




1. To evaluate the relationship between NaHS concentration and its effect on tissue 
viability. To characterize cell metabolism of H2S, cardiomyocytes were exposed to 
NaHS over 1 hour and the subsequent levels of H2S in the cell culture were assessed. 
The cardiomyocytes were then assessed using metabolic activity and viability assays. 
Therefore, we investigated the effect of varying NaHS concentrations on cell 
viability. 
2. Hydrogels are biocompatible polymers with a wide variety of applications. By 
controlling the degree of crosslinkage and gelatin acidity, absorption and release rates 
of NaHS were varied until a desired time-release profile of NaHS is achieved. W e 
investigated crosslinkage in the fabrication of gelatin microspheres in order to 
control the release of H2S.  
3. In order to analyze the clinical applicability of the previously developed 
concentration and release profiles, the biological efficacy of NaHS treatment was 
analyzed in comparison to existing methods of organ storage. The most 
commonly used method today is hypothermic storage in UW solution. We analyzed 
three possible outcomes of applying microsphere delivery of NaHS to isolated hearts. 
First, we determined whether H2S enhances, hinders, or has no effect on preservation 
with UW solution. Second, the viability effects of a fixed initial concentration of H2S 
were compared to that of constant replenishment of H2S, which was accomplished 
using gelatin microspheres. Lastly, an experiment was conducted to verify whether 
gelatin microspheres have an effect on heart viability. The extension of tissue survival 




With the completion of these specific aims, we have developed a new, promising 
method for heart storage that has the potential to reduce I/R injury and ROS and can be 





O rgan Storage 
Introduction 
Organ transplantation today is limited by the time an organ can remain viable 
outside the body. This time range influences several key decisions (e.g. where the heart 
can be transported and thus where the surgery can be conducted) that ultimately 
determine the number of patients who can successfully receive a transplant. For the 
human heart, clinical storage time is limited to four to six hours under current storage 
methods as the extent of ischemia-reperfusion (I/R) injury is proportional to storage time 
(Jamieson and Friend 2008). The standard method of organ transplantation today is static 
cold storage of the organ in solution, such as ViaspanTM solution. Widely known as the 
UW solution, this solution was the first to be thoughtfully designed for organ 
preservation and is widely used clinically. The various components of the UW solution 
have specific functions in maintaining the viability of the organ during storage. There 
have been many additions and alterations made to the UW solution ever since it was first 
designed in an attempt to improve organ preservation.  
Heart Transplantation Milestones 
Heart transplantation research began in 1956 in the United States when Watts R. 
Webb and James Hardy investigated both heart and lung transplantations in dogs. By 
1957, Webb was able to demonstrate limited survival in dogs undergoing heart 
transplantations; with the success of the lung transplant in 1963, research moved on to 




heart. Retrograde gravity flow of cold, oxygenated blood through the coronary sinus 
(Figure II-1) was used as the preservation technique (Lower, Stofer et al. 1961; Hardy 
and Chavez 1968; Hardy 1999). After the heart was transplanted, it was warmed back to 
37°C and defibrillated, restoring function immediately. Since the heart is a highly 
innervated organ, transplantations bring about complete extrinsic autonomic denervation, 
which results in almost total loss of the myocardial stores of catecholamines (Daggett, 
Willman et al. 1967). The inability of a trans-species heart to reinnervate contributed to 
the failure of the above study (Daggett, Willman et al. 1967). In addition, the chimpanzee 
heart was too small to sustain human functions. Other factors that led to the death of the 
state of intermittent shock.  
The first successful human heart transplantation was conducted in Britain in 1967. 
However, the recipient died 18 days later of pneumonia. The first heart transplantation in 
which the recipient did not die shortly after the procedure occurred a year later and was 

















F igure I I-1: Heart preservation in first 
transplant. Retrograde gravity flow of chilled 
oxygenated blood through the coronary sinus. 





Donor Management and Heart Extraction Today: 
Today, organ harvesting in the United States undergoes many regulatory steps 
meant to standardize and maintain the quality of transplantation procedures. Physicians 
identify potential donors using patient history and immunization records. Before 
harvesting can occur, the donor must be identified, declared brain-dead, and have given 
consent. Next, donors undergo tests for HIV, Hepatitis B, Hepatitis C, Epstein-Barr virus, 
and the toxoplasma antibody. Negative results must be obtained for each of these tests to 
en
A blood cell count and blood typing are also performed, followed by a detailed analysis 
of organ function, in order to ensure the viability and quality of organs before they are 
transplanted into the recipient. To assess the viability of donor organ health for the heart, 
a standard test includes electrocardiograms. Additionally, changes in troponin and 
creatine phosphokinase are monitored. If all tests prove negative, an echocardiogram is 
then ordered to assess morphology (Tatarenko 2006). 
Removal of the heart is only conducted on brain-dead, heart-beating donors. In 
the procedure, donor bodies must be maintained at 90 mmHg systolic blood pressure and 
a heart rate less than 100 bpm. After a stand-off period has occurred to ensure the death 
of the donor, surgeons cross-clamp the aorta and perform in situ perfusion through a 
single cannula. Organs are rapidly cooled because the core body temperature is reduced 
by the perfusion. Moreover, subsequent graft function is significantly improved by a 
flush with streptokinase (an anticoagulant) at a flow pressure of 150 mmHg; it has been 




The heart is then stored in UW solution at a reduced temperature of 4oC (Tatarenko 
2006). 
Preservation injury 
When organs are removed, they unavoidably undergo a period of warm ischemia, 
typically followed by a period of cold ischemia in a low oxygen preservation solution. 
Ischemic-reperfusion (I/R) injury is the biphasic damage to tissue during periods of 
metabolic stress due to low blood flow and oxygen, followed by oxidative stress 
accompanying re-oxygenation. It is a paradoxical situation in that the restoration of blood 
flow rescues the ischemic tissue and reduces the infarct size, or area of localized dead 
tissue, but reperfusion itself contributes to tissue death. I/R injury manifests itself in a 
variety of organs and tissues, ranging from the brain, to skeletal muscle. A familiar 
example is injury after blood flow is restored following a myocardial infarction; I/R 
injury contributes to up to half of the infarct size. This damage to the heart leads to a 25% 
likelihood of cardiac failure (Yellon and Hausenloy 2007), and an array of dysfunctions 
like stunning (mechanical weakness), no-flow (areas of impeded perfusion), and 
arrhythmias (abnormal heart rhythm). 
The mechanisms driving I/R injury are complex and still not fully understood 
(Henderson, Singh et al. 2010). The general progression is postulated to occur in two 
stages: an ischemic stage, and a reperfusion stage. During ischemia, oxidative 
phosphorylation is compromised because there is limited oxygen. The depletion of ATP 
impacts essential cellular self-maintenance processes and anabolic pathways, 
compromising the production of essential components needed to keep the organ alive. 




Taketomi et al. 2006). Lactate and other metabolic by-products like hypoxanthine (a 
byproduct of ATP) build-up, as the organ uses anaerobic metabolism to support basic 
homeostatic processes (like the sodium potassium pump) in the low-oxygen environment. 
These become fuel for ROS generation upon the re-introduction of oxygen.  
During ischemia, much calcium is accumulated in the cell, particularly in the 
mitochondria (Nishida, Sato et al. 2009). This calcium overloading is a critical event in 
the progression of I/R injury. Calcium accumulates inside the cell through various 
mechanisms related to ionic imbalance due to energy depletion. With less ATP to power 
the membrane Na+/K+ pump, sodium enters the cell down its concentration gradient. 
Sodium is exchanged for calcium via a membrane-exchange pump (Dorweiler, Pruefer et 
al. 2007), and indirectly opens voltage-gated calcium channels (Storey 2004). The 
mitochondria uptakes calcium, which is driven by the ionic potential across the inner-
mitochondrial membrane. The high calcium concentration inside the mitochondria has an 
important role in reperfusion, as it contributes to the opening of the mitochondria 
transition pore (MPT). Proteases and phospholipases leak out of lysosome in high-
calcium environments. These and other calcium-activated enzymes destroy proteins or 
lipid membranes, making the cell more susceptible to rupture (Murphy and Steenbergen 
2008), and conduct apoptotic signaling cascades  (Dorweiler, Pruefer et al. 2007).  
The low-oxygen environment antioxidant defenses and 
promotes the generation of ROS. The mitochondria, under normal conditions, uses 
oxygen quite efficiently, converting 95% of its oxygen to ATP without production of 
ROS (Dorweiler, Pruefer et al. 2007), highly reactive species that can directly damage the 




ROS is generated due to inefficient electron transfers to the limited oxygen present 
(Becker 2004), and these can further damage the electron transport chain (ETC), leading 
to more ROS generation in a dangerous, self-propagating cycle (Roth and Nystul 2005). 
ROS generation is possible because catalase, dismutase, and the glutathione peroxidase 
system, the enzymes responsible for safely neutralizing superoxide to peroxide to water, 
do not function well in ischemia (Becker 2004), leading to a build-up of hydrogen 
peroxide, which in turn, generates the hydroxyl radical, a particularly dangerous ROS.  
 short amount of time. This ROS 
generation is fueled by the metabolic byproducts that accumulated during ischemia, and 
these ROS directly damage cellular structures and lead to tissue necrosis (Jamieson and 
Friend 2008), as well as signal inflammatory response (Dorweiler, Pruefer et al. 2007). 
The mitochondria are  sites of particular interest as it plays a critical role in mediating I/R 
injury. A substantial portion of damage to the electron transport chain occurs during 
ischemia. The MTP is a non-specific channel in the inner mitochondrial membrane that 
opens under conditions of high matrix calcium and ROS, conditions that occur during the 
start of reperfusion (Murphy and Steenbergen 2008). The opening of the MTP leads to 
the dissipation of proton gradient and the inability of mitochondria to make ATP, which 
leads to cell death. Due to membrane disruption in the mitochondria by ROS, cytochrome 
c is released, which leads to the activation of caspases and apoptotic pathways (Chen, 
Camara et al. 2007). Thus, the extent to which MTP remains open largely determines the 
extent of reperfusion injury. The most effective therapeutic measures, like ischemic 




opening, including high calcium loading and ROS production (Halestrap, Clarke et al. 
2007). 
Preservation Methods 
For the human heart, clinical ex vivo storage time is limited to four to six hours. 
Additionally, there is an organ donor shortage; as of February 2011, 3,215 patients were 
registered on the waiting list for a heart transplant. However, in 2010 there were only 
2,135 donors, all deceased, leaving at least 1,000 still in need (Organ Procurement and 
Transplant Network 2011). Since quality organs are limited in supply and always high in 
demand, prolonging storage time can expand supply by expanding the geographic range 
of potential donors. 
The quality of a donor organ is determined by a variety of factors, including 
donor age and donor management prior to procurement of the organ. The duration of 
hypothermic storage and the perfusion techniques utilized to protect organs from 
ischemia-reperfusion injury  is also extremely important. 
Static cold storage involves the use of low temperatures and UW solution, a 
commonly used storage solution with its own advantages and disadvantages. The 
additives of UW solution greatly reduce swelling over previous methods, while 
hypothermic preservation reduces metabolism and therefore metabolic waste. 
Additionally, the solution provides rapid cooling and a sterile environment. Since UW 
solution lowers aerobic metabolism, it induces anaerobic metabolism, whose end-
products generate oxygen free radicals, leading to I/R injury. Inflammation, tissue 




Other methods of organ storage are also available, such as the use of 
perfluorocarbons, which is an additive that induces the cells to absorb oxygen more 
efficiently. However, despite nearly two decades of research into potential additives to 
cold static storage solutions, heart storage time has yet to exceed 8 hours (Skrzypiec-
Spring, Grotthus et al. 2007). More existing methods include hypothermic machine 
perfusion, used mainly for kidneys, and normothermic perfusion, which is performed at 
37OC (Jamieson and Friend 2008). Both are promising, but are limited in their 
applicability due to the requirement of relatively large pieces of equipment to maintain 
storage conditions. 
The underlying concept behind most preservation methods is the suppression of 
metabolism via hypothermia. Despite its limitations, the UW solution in conjunction with 
hypothermia is the most common method of preservation today. The UW solution can 
preserve the liver, pancreas, and kidney for up to two days, and its effectiveness can be 
attributed to various cell impermeant agents that prevent cells from swelling during cold 
ischemic storage. In addition, it contains agents that stimulate recovery of normal 
metabolism after reperfusion by amplifying the antioxidant capacity of the organs or by 
stimulating high-energy phosphate generation (Southard and Belzer 1995). When used 
with machine reperfusion, the perfusion fluid is modified by utilizing gluconate instead 
of lactobionate, which is ineffective in continuous machine perfusion for unknown 
reasons. Machine perfusion has yielded the best-quality and longest-term preservation as 
it allows for continual delivery of oxygen and substrates to the organ for the synthesis of 





Before the UW solution was formulated, general organ preservation was limited 
to four to six , and heart preservation times were far worse. 
first created when a perfusate derived from human plasma 
preserved a kidney for three days with continuous machine perfusion at 6-8oC. The final 
perfusate, cryoprecipitated plasma, became the standard perfusion fluid for human 
kidneys. However, because it was derived from human plasma, there were concerns 
regarding its potential for spreading disease. Subsequent research focused on synthetic 
perfusates. Despite the success of the subsequent perfusates, none were applicable to 
general organ preservation. Furthermore, in the 1970s, organ rejection and 
immunosuppressive drugs became the forefront of research. Once immunosuppressive 
drugs such as cyclosporine were developed, the focus shifted to better methods of organ 
preservation. Thus, the development of UW solution became the focus of research in the 
early 1980s.  
Overall, UW solution is highly efficient in preserving the liver, pancreas, and 
kidneys. UW solution organ preservation at 0-5oC meets most clinical needs, with the 
transplant survival rate for these organs at nearly 90%. However, it remains difficult to 
preserve the heart and lungs for more than 4-6 hours, and this time cap also limits the 
geographical range from which a donor heart can be procured. The difficulty of heart 
preservation is twofold: heart function is vi the high 
content of contractile protein means that energy stores are used rapidly - during cold 
storage, organs lose 95% of their ATP within 2-4 hours. This loss does not compromise 
heart viability as it quickly regenerates the ATP a few days post-transplantation. 




contracture when ATP concentration falls below a certain point (Stringham, Southard et 
al. 1992; Southard and Belzer 1995). Unlike any of the other organs, the heart must 
regain near-optimal functional conditions immediately upon transplantation to support 
the circulation of the recipient. Therefore, it is vital that the heart suffers minimal 
preservation injury. The primary goals of cardiothoracic transplantation are to achieve 
successful preservation of the heart and lung for 24 hours or more (Southard and Belzer 
1995).  
The UW Solution 
While many of UW Table II-1) were originally included 
for their proven ability to decrease cellular edema, others were included simply because 
they were common to other organ preservation solutions and had not been shown to have 
detrimental effects (Askenasy, Vivi et al. 1996). Research has clarified how these other 
components also protect the heart by combating three obstacles of preservation: impaired 
energy metabolism, acidosis, and radical oxidative species (Jeevanandam, Barr et al. 
1991). Further research has attributed additional myocardial benefits to the calcium-
chelating properties of UW solution.  
 
Substance Amount 
K+-lactobionate 100 mM 
KH2PO4 25 mM 
MgSO4 5 mM 
Raffinose 30 mM 
Adenosine 5 mM 
Glutathione 3 mM 
Insulin 100 U/L 
Bactrin 0.5 mL/L 




Allopurinol 1 mM 
Hydroxyethyl starch 50 g/L 
 
Table I I-1: Components of the original UW solution. This version was originally used to preserve the 
pancreas. (Askenasy et al., 1996) 
 
Benefits of Cold Storage 
Most enzymes exhibit a 1½- to 2-fold decrease in activity for every 10°C decrease 
in temperature. Therefore, cooling organs from 37°C to 0°C can decrease metabolic rate 
12-13 fold and extend preservation time by 12-13 hours because most organs can tolerate 
30-60 minutes of warm ischemia without complete loss of function (Sumimoto, Dohi et 
al. 1992). The problem with this theory is that hypothermic storage also activates 
processes that will ultimately be deleterious to the preserved organ, including cellular 
swelling, extracellular edema, acidosis, depletion of metabolic substrates, reperfusion 
injury, calcium overload, and endothelial injury (Askenasy, Vivi et al. 1996). Although 
normothermic preservations are possible with continuous perfusion (Askenasy, Vivi et al. 
1999), previous studies have shown that UW solution is limited to hypothermic storage 
(Rosenkranz 1995). 
Cellular Edema 
Preventing cellular edema is often considered one of the most significant goals of 
organ preservation (Karck, Vivi et al. 1992), as deficient volume regulation is an early 
indicator of cell injury (Jahania, Sanchez et al. 1999). During ischemia and hypothermia, 
s to cellular swelling (Belzer and Southard 
1988). Therefore, many preservative solutions are composed of impermeable molecules 




solution have been shown to decrease transcapillary and osmotic fluid transport, which 
reduces cellular swelling (Maurer, Swanson et al. 1990): lactobionate, an impermeant 
anion (358 Daltons); raffinose, a saccharide with a relatively large molecular mass (594 
Daltons); and hydroxyethyl starch, a stable, non-toxic colloid that prevents expansion of 
the extracellular space and interstitial edema (Schubert, Vetter et al. 1989). Hydroxyethyl 
starch is sometimes excluded in experimental modifications to UW solution. Its exclusion 
seems to improve cardioprotection by reducing the viscosity of the solution, thereby 
permitting faster organ perfusion (Jovanovic, Lopez et al. 1998). Using dextran-40 in its 
place may benefit cardioprotection (Snabaitis, Shattock et al. 1997).  
Cellular swelling can also be caused by an influx of sodium ions in both 
normothermic and hypothermic conditions (Jovanovic, Lopez et al. 1998). Consequently, 
regulation of factors affecting sodium transmembranal transport, such as Na/K/Cl2 
cotransport, NaH antiport, and Na+ voltage-gated channels, can influence 
cardioprotection. This effect is demonstrated by the experimental correlation between 
inhibition of sodium transmembranal transport and reduced water accumulation during 
ischemia (Maurer, Swanson et al. 1990). 
Although UW solution and several of its constituents have been repeatedly 
correlated with a reduction in cellular swelling, some research challenges the idea that 
such reduction or prevention of edema is a causative factor in cardiac preservation 
(Jahania, Sanchez et al. 1999). Data showing that membrane deterioration precedes 
cellular swelling suggests that the integrity of the sarcolemmal membrane is an 
alternative and more accurate indicator of ischemia injuries (Maurer, Swanson et al. 




production of reactive oxidative species, may weaken the sarcolemmal membrane and 
cause necrosis during reperfusion (Rosenkranz 1995).  
Metabolic Suppression and ATP Recovery 
Myocardial metabolism produces ATP that is used to maintain intracellular 
homeostasis and a functional contractile apparatus (Pacher, Nivorozhkin et al. 2006). 
Decreased metabolic activity prevents the production and accumulation of toxic waste 
products, such as free radicals (Burgmann, Reckendorfer et al. 1992). However, a 
myocardial preservation solution must maintain a certain level of ATP for functional 
recovery because the heart, unlike other organs, can develop an irreversible contracture 
during preservation or reperfusion, known as ischemic contracture (Jahania, Sanchez et 
al. 1999). In UW solution, adenosine helps stimulate the synthesis of ATP to be used in 
regenerating Na+/K+ ATPase pump activity and other energy-requiring steps of 
metabolism, which in turn facilitates rapid defibrillation and recovery of myocardial 
function (Burgmann, Reckendorfer et al. 1992).  
As an intracellular hyperkalemic solution, UW solution also contains a high 
potassium concentration that mimics intracellular ionic conditions (Burgmann, 
Reckendorfer et al. 1992). The high extracellular potassium content equilibrates 
extracellular and intracellular ionic concentrations; this minimizes the ionic gradient and 
subsequent ion transfer across membranes, which allows more rapid spontaneous 
defibrillation upon reperfusion (Jovanovic, Lopez et al. 1998)
importance in UW solution is due to its depolarizing effect, depolarization in cardiac 
preservation has been associated with arrhythmias and the activation of enzyme systems 




solution may be a more effective cardioplegic agent, inducing cardiac arrest without these 
side effects (Maurer, Swanson et al. 1990; Jahania, Sanchez et al. 1999). However, other 
data also suggests that adenosine protects against such effects by inhibiting 
hyperkalemia-induced Ca2+ loading, a mechanism that could contribute significantly to 
ventricular dysfunction (Jahania, Sanchez et al. 1999). Additionally, the mere presence of 
 solution did not confer the same protective effects as 
potassium in UW solution, suggesting a complex mechanism of potassium action in UW 
solution (Maurer, Swanson et al. 1990). 
Acidosis 
Although hypothermic storage slows reaction rates and delays cell death, UW 
solution and ischemic storage induce reduced oxygen consumption that promotes the use 
of anaerobic glycolysis for ATP production (Rosenkranz 1995). Anaerobic glycolysis 
produces lactic acid and hydrogen ions during ischemia, which can injure cellular 
organelles and activate macrophages that initiate cytokine production and an 
inflammatory response (Pacher, Nivorozhkin et al. 2006). In UW solution, potassium 
phosphate and magnesium sulfate, along with other buffers, minimize pH changes caused 
by lactate production (Burgmann, Reckendorfer et al. 1992). 
Oxygen Radical Scavenging 
In addition to radical oxygen species (ROS) being formed as waste products of 
metabolic activity during organ storage, the reintroduction of blood flow and oxygen 
during reperfusion can lead to the creation of ROS (Murphy and Steenbergen 2008). The 
hydroxyl radical is one of the most damaging species formed during ischemia and 




radical scavenger that reduces hydroxyl radical levels as well as other cytotoxic agents, 
such as H2O2, lipid peroxides, disulfide, and ascorbate (Rosenkranz 1995). Because 
glutathione is depleted during ischemia, UW solution also contains glutathione (Belzer 
and Southard 1988). However, it has been suggested that the glutathione is oxidized to a 
less effective form, and has little effect on preservation (Pacher, Nivorozhkin et al. 2006). 
Allopurinol is another ROS scavenger in UW, mainly targeting xanthine oxidase, but it 
also acts on other ROS (Pacher, Nivorozhkin et al. 2006). The protective effects against 
myocardial I/R injury have been demonstrated in both animal and human models (Amir, 
Rubinsky et al. 2003; Amir, Rubinsky et al. 2004). Hypothermic conditions also 
contribute to the reduction of free-radical generation in isolated hearts (Scheule, Jost et 
al. 2003). 
Calcium Regulating Properties 
In addition to the previously identified protective effects of UW solution, calcium 
Several components of UW solution prevent the accumulation of intracellular calcium, 
which can lead to cellular dysfunction and death. Lactobionic acid, known for regulating 
intracellular water accumulation, also effectively binds calcium. Increasing 
concentrations of lactobionic acid have been correlated with decreasing concentrations of 
free calcium, especially at higher pH values when tested at a pH range of 5 to 8 
(Burgmann, Reckendorfer et al. 1992). Furthermore, potassium phosphate and 
magnesium sulfate may indirectly regulate calcium concentrations by contributing to the 




The UW solution contains various components designed to effectively preserve 
hearts in storage. Research has demonstrated which components are responsible for 
which protective effects, including the reduction of metabolic activity through cold 
storage, the prevention of cellular edema, and ATP recovery. Furthermore, UW solution 
has been shown to prevent acidosis and the accumulation of ROS, and to also have 
calcium-chelating properties. Although these characteristics make UW an effective 
preservation solution, the advantages of some components, such as potassium, are still in 
question. In addition, some studies have investigated other substances with great potential 
for maximizing the cardioprotective effects of the UW solution.  
Additives to UW Solution 
While UW solution has been a major step in preserving hearts, it is not optimal 
and can be improved. In order to combat I/R injury, there have been continuous 
developments of additives that increase heart viability (Table II-2). 
Additive Proposed Benefits Experimental F indings 
2,3-
Butanediol 
By adding 2,3-butanediol (a 
cryoprotectant agent that 
prevents ice crystal formation) 
and preserving hearts at subzero 
temperatures, rat hearts can be 
preserved for longer periods of 
time and retain viability. 
In rat hearts with 2% 2,3-butanediol 
preserved at -1ºC, the left ventricle 
had significantly better recovery with 
significantly higher amounts of 
creatine kinase and lactate when 
compared to the control group 








Antifreeze proteins are able to 
bind ice crystals and inhibit 
recrystallization, which allows 
subzero preservation. 
Hearts with UW solution and AFP 
were preserved at -1.3ºC, and the 
viability of the hearts was 
significantly better after reperfusion. 
There was also better myocyte and 
mitochondrial structural integrity 
(Fischer and Jeschkeit 1996). 
Cariporide 
 
Cariporide is an NaH antiport 
inhibitor that can improve 
cellular integrity after ischemia 
and reperfusion. 
Addition of cariporide in UW 
solution along with constant 
perfusion resulted in increased 
stroke-work index and decreased 
levels of troponin I in pig hearts 






By adding a selective 
endothelin-A receptor 
antagonist (to block receptors 
for blood-constricting proteins) 
to oxygenated UW solution, 
edema and vasoconstriction can 
be minimized. 
After preservation for 24 hours using 
perfusion with oxygenated UW 
solution and endothelin-A receptor 
antagonist, the percent recovery rate 
of cardiac output and coronary flow 




Hyaluronidases are a family of 
enzymes that degrade 
hyaluronic acid. 
In hearts treated with hyaluronidase, 
edema formation was reduced; 
coronary flow, metabolic recovery, 
and stroke volume were improved as 





Additive Proposed Benefits Experimental F indings 
Lazaroid 
 
Lazaroid is an inhibitor of iron-
mediated lipid peroxidation. 
This compound has been 
previously shown to reduce 
ischemia-reperfusion injury by 
reducing free radicals. 
Rabbit hearts pre-treated with 
lazaroid had less ischemia-
reperfusion injury, better ventricular 
function, and lower lipid peroxide 
levels (Kuroda, Kawamura et al. 





mixture consisting of varying 
concentrations of inosine, 
guanosine monophosphate, 
cytidine, uridine, and thymidine 
has a positive effect on protein 
and energy metabolism. This 
combination helps restore 
myocardial ATP concentrations 
and is used in forming high-
energy phosphate. 
Recovery of heart rate, aortic 
pressure, rate pressure, stroke 
volume, and stroke work was 
increased. Coronary flow and aortic 
flow also increased. Coronary 
vascular resistance was decreased 





compounds derived from 
hydrocarbons with fluorine 
replacing hydrogen. The 
compound has a high capacity 
to dissolve oxygen and a low 
oxygen-binding constant, which 
allows better oxygen transfer. 
In a heterotropic rat heart transplant 
model, preservation time was 
extended up to 48 hours (Fremes, 




Additive Proposed Benefits Experimental F indings 
Rho-Kinase 
Inhibitor 
By adding a Rho-kinase 
inhibitor to UW solution, the 
detrimental effects of the Rho-
kinase transduction pathway 
can be prevented and provide 
better myocardial preservation 
and reduce ischemia-
reperfusion injury. 
In rabbit hearts where Rho-kinase 
inhibitor was added to UW solution, 
coronary blood-flow and heart rate 
increased. Endothelial nitric oxide 
synthase mRNA levels increased 4-
fold, which reflects a positive effect 
on endothelial function (Lee, 







Modifying the cation 
concentrations has been shown 
to be beneficial and may 
enhance cardiac recovery after 
extended preservation. 
Developed pressure was increased 
with 0.1 mmol/L calcium and 20 
mmol/L magnesium. Coronary flow 
was recovered best with 15 mmol/L 
magnesium. Diastolic function was 
reduced. Addition of calcium in 
concentrations of 2.5 mmol/L was 





High potassium concentrations 
are suggested to be related to 
coronary artery endothelial 
damage. 
In one study, lowering potassium 
concentration resulted in better 
protection of the endothelium, which 
correlated to increased nitric oxide 
release (Hardy 1999). In another 
study, lowering potassium 
concentration in a non-starch UW 
solution decreased the protective 
effect by 30%. 
Table I I-2: Additives to UW solution that have improved heart viability or extended ex vivo storage time. 
Antifreeze proteins (AFP) allow fish and insects to survive freezing temperatures 




winter flounder and AFP III from ocean pout have been successfully utilized to improve 
heart preservation. Rat hearts have been preserved in UW solution containing AFP at 
concentrations of 15-20 mg/cc for 2-6 hours at -1.1ºC to -1.3ºC (Kuroda, Kawamura et al. 
1995; Matsumoto and Kuroda 2002). While three of the four hearts in the control group 
froze and died, electron microscopy showed that the myocyte structure and mitochondrial 
integrity were preserved in the AFP-preserved hearts. The control hearts had disrupted Z-
lines, mitochondrial swelling, and destruction of myocyte structure. It was concluded that 
AFPs prevent the freezing of hearts in subzero preservation, and that using subzero 
preservation can increase storage time and viability of preserved hearts (Kuroda, 
Kawamura et al. 1995; Matsumoto and Kuroda 2002). 
Cariporide, a NaH antiport inhibitor (HOE642) has also been shown to have 
beneficial effects when used with UW solution. In the experimental group with 
cariporide, the stroke-work index was higher and malondialdehyde levels were lower, as 
revealed by light microscopy. This study implies that cariporide has potential to improve 
recovery and decrease myocardial damage (Kobayashi, Tanoue et al. 2008). 
Perfluorocarbons (PFCs) are additives that maintain a constant supply of oxygen. 
PFCs have small oxygen binding constants, which allow oxygen to be released more 
easily in solution, thereby making it an excellent carrier. In experiments conducted with a 
two-layer method, which utilizes oxygenated UW solution and PFCs, ATP production 
continued during storage, leading to longer preservation times (Rosenfeldt, Conyers et al. 
1996).  
Signaling pathways related to I/R injury involving Rho and Rho-kinase have also 




organization, cell adhesion, cell migration, and endothelial nitric oxide synthase levels. 
Inhibiting Rho-kinase would preclude those events and could consequently increase heart 
viability. Japanese white rabbit hearts were immersed in UW solution with or without 
inhibitor for 24 hours. The performance of the left ventricle was measured using the 
Frank-Starling curve, indicating that the inhibitor group produced higher aortic flow with 
less left atrial pressure. Coronary blood flow and heart rate was measured using a 
Langendorff apparatus. Phosphorylated myosin light chain and nitric oxide synthase 
mRNA levels were measured as indicators of effectiveness of the inhibitor and 
endothelial function, respectively. Low levels of myosin light chain indicated that the 
inhibitor had worked and there was increased blood flow, heart rate, and endothelial 
function. Overall, the addition of the inhibitor could be used to prevent myocardial 
damage during preservation (Lee, Drinkwater et al. 1996). 
Varying the concentrations of the potassium, magnesium, and calcium ions has 
produced different effects. Evidence suggests that the high concentration of potassium 
currently in UW solution is responsible for endothelial damage. One study in Australia 
compared the effect of using a starch-free UW solution with a lowered potassium 
 solution. When the potassium concentration was lowered, 
the protective effect was compromised (Fremes, Zhang et al. 1995). However, in another 
study conducted by the UCLA Medical Center, there were differing results. When 
potassium concentrations were lowered to 25 mEq/L from 129 mEq/L, there was better 
protection of the endothelium, which was measured by an increase of nitric oxide release 




research to be conducted on the effect of potassium concentration on endothelial function 
and viability.  
Calcium concentrations from 0.025 mmol/L to 10 mmol/L have also been 
researched. At the maximum concentration, the calcium was detrimental and decreased 
the developed pressure. The concentration that resulted in the highest developed pressure 
was 0.1 mmol/L. Coronary flow was significantly better than in UW solution without 
additives at 15 mmol/L. When the effect of the cations is compared cumulatively, the best 
developed pressure was achieved by 0.1 mmol/L calcium and 20 mmol/L magnesium. 
Consequently, the addition of calcium and magnesium could enhance recovery from 
preservation (Oshima, Morishita et al. 1999; Tsutsumi, Oshima et al. 2001).  
Machine Perfusion 
Cold storage is limited on a conceptual basis. The goal is to limit metabolism in 
order to induce a state of suspended animation, which would theoretically allow the heart 
to remain outside of the body longer for transportation. However, the heart never truly 
hibernates; it uses anaerobic metabolism, which leads to the build-up of dangerous ROS 
(Ozeki, Kwon et al. 2007) that subsequently react with nearly every molecule in the cell, 
impacting protein functions and damaging the cell. 
oxygen scavengers help alleviate these effects, storage time is limited, and I/R injury 
persists. Additionally, this leads to a buildup of metabolic waste and severe depletion of 
ATP energy stores (Opie 2004). 
Machine perfusion (MP) is advantageous because it removes metabolic waste as it 
is generated, which prevents acidosis (Collins, Moainie et al. 2008). In addition, MP 




Without a continually replenishing oxygen supply, the heart must work 20 times harder to 
produce ATP (Conte and Baumgartner 2000). MP has already been well established for 
renal allografts and transplants, and the Organ Care System, a proprietary perfusion 
system, has already received FDA approval for kidney transplantations. MP can even use 
the UW solution as a perfusate during the ex vivo period. 
Despite its benefits, MP has raised several concerns that have prevented its 
adoption in clinical practice. Myocardial edema is one strong concern, but it has been 
proven to have no effect on function after the ex vivo storage period (Tsutsumi, Oshima et 
al. 2001; Poston, Gu et al. 2004; Ozeki, Kwon et al. 2007). The two other main concerns 
are cost and technical complexity. Cold storage cannot be surpassed in these terms 
because of its simplicity. Additionally, the UW solution is extremely cost-effective, 
available commercially, and readily made from a simple recipe. In contrast, MP requires 
maintenance: it is currently a bulky machine and not easily transportable. However, these 
concerns can be easily addressed with time and research.  
The two main types of MP are normothermic and hypothermic. As their names 
imply, normothermic perfusion is conducted by heating the perfusate to body 
temperature, 37°C, and is generally conducted using a perfusate that is based on whole 
blood, often with some additives like antibiotics. Hypothermic MP is conducted by 
cooling the perfusate to 4°C and generally uses a synthetic perfusate.  
Normothermic MP has been one of the most successful techniques in extending ex 
vivo storage time for cardiac transplants. Although the technique was advantageous 
because it was used for heart and lung preservation simultaneously, it was abandoned due 




not be applicable for distant thoracic organ procurement (Collins, Moainie et al. 2008). 
However, the Organ Care SystemTM has recently shown promise for distant heart 
procurement although its cost and size are still issues. It has been approved in Europe for 
marketing, and is currently undergoing FDA testing. 
Hypothermic MP has also been demonstrated to sustain aerobic metabolism 
(Collins, Moainie et al. 2008), and should maintain cell integrity and vital functions much 
better than anaerobic metabolism. However, MP does have its challenges. While 
successful perfusate and pump parameters are known, the lack of unified research has 
created confusion in the field. Myocardial edema has been a significant concern, but does 
not appear to affect heart function once blood flow has been restored (Sakaguchi, 
Taniguchi et al. 1998). One of the concerns with hypothermic MP has been that 
metabolism cannot be observed. Although the heartbeat can be observed in normothermic 
MP, this is not seen in hypothermic MP. Additionally, hypothermic MP has been 
observed to revive only 50% of hearts; this is theoretically due to the already sustained 
I/R injury (Amir, Rubinsky et al. 2003; Amir, Rubinsky et al. 2004). 
O ther Alternatives 
The purpose of cold storage at 4OC is to reduce metabolic rate and biochemical 
reactions, to reserve energy reserves, and to avoid waste build-up. However, low 
temperature and ischemic conditions limit ATP synthesis, thus limiting vital cellular 
functions. New techniques have been derived from finding optimal oxygenation and 
temperature conditions for ATP-synthesis (Jamieson and Friend 2008). Oxygenation of 
storage solution helps maintain mitochondrial function for ATP synthesis and antioxidant 




method) have improved ATP recovery and maintained antioxidants better than cold 
storage (Matsumoto, Kuroda et al. 1996). The mild two-layer method, a variation of the 
two-layer method at 20OC, has led to faster ATP recovery and resuscitation of pancreases 
(Stubenitsky, Booster et al. 2000). Studies have shown the potential of normothermic 
preservation, which involves the perfusion of cell-culture media or blood-based perfusate 
near physiological temperatures, to lengthen storage times and improve graft survival 
(McAnulty, Reid et al. 2002). Another development in the research of additives to cold 
storage solution is trophic factor supplementation. Adding various growth factors 
prolonged storage time of kidneys, possibly by accelerating regeneration of tissue or 
activating protective signaling cascades (Nakao, Kaczorowski et al. 2008). Together, 
these new generation methods represent an opposite approach to preservation, namely 
creating conditions that support rather than inhibit the metabolism of the organ during 
storage. 
One potential organ preservation improvement lays in unlocking cytoprotective 
genes inherent in organs. HO-1 is a particularly important gene responsible for breaking 
down heme (which converts H2O2 into more reactive free radicals) into cytoprotective 
molecules CO and biliverdin. HO-1 is a heat shock protein that is expressed in various 
stress situations, such as oxidative stress, hot temperature, ischemic preconditioning, and 
chemicals (Jamieson and Friend 2008). The advancement of gene manipulation has made 
it possible to transfer protective genes to the preserved organ through an engineered virus 
vector. Successful experiments have transferred various genes including HO-1, Bcl-xl, 




It is recognized that improvement of the cold-storage method has met an impasse 
due to the inherent problems related to its mechanism. Temperature reduction does 
indeed lower metabolism by a factor of 10-12, but anaerobic metabolism continues 
(Jamieson and Friend 2008; Nakao, Kaczorowski et al. 2008). With ischemia: 1) end-
products of metabolism such as protons, lactate, and hypoxanthine  build-up (Cotter 
2003), 2) ATP levels drop to 50% of normoxic levels within 4 hours of ischemia (Hale, 
Dai et al. 2008), 3) Impairment of mitochondrial antioxidant defenses occurs, 4) Calcium 
influx and leakage from mitochondria are prevalent. For these reasons, the time in cold 
storage is proportional to the extent of ischemia-reperfusion (I/R) injury. While perfusion 
techniques appear to attenuate these problems, their use is restricted due to the cost and 
relative complexity of machinery. Similarly, the setbacks of technology-intensive gene 
therapy include issues of practicalities making it inadequate for organ preservation.  
Conclusions 
While there has been significant money spent and research conducted in 
improving the UW solution, these findings have not translated into clinical practice. 
Factors such as ion concentrations, mainly potassium and calcium, have yet to be 
optimized. The current configuration is considered an intracellular type of preservation 
solution because its high potassium content mimics the intracellular environment. 
However, varying the potassium and calcium concentrations within UW solution has 
been reported to significantly improve both the viability of the heart after preservation, 
and extend the time the heart can be preserved. In addition, there has been no research 




There are also entire classes of compounds that have not been investigated for 
heart preservation. One such possibility is the usage of compounds that have been shown 
to induce a hibernative state. A new class of molecules called gasotransmitters has been 
of interest in this application. Gasotransmitters are a group of molecules that are toxic in 
higher concentrations, but induce extremely low metabolism with no permanent side-
effects at lower concentrations. Some research into gasotransmitters has been conducted, 
but there is not enough information to make any conclusions regarding their potential 
benefits to cardiac preservation (Staples & Brown, 2008). It may be that some of these 
components will interfere with the mechanisms of action of other components, but once 
the correct configuration is identified, this may lead to a solution that is a very significant 
improvement over the current UW solution. 
Hydrogen Sulfide 
Introduction 
Hydrogen sulfide (H2S) is a small, gaseous molecule primarily known for its 
toxicity and the danger it poses (See Table II-3for chemical properties). It is produced by 
biological decomposition, crude petroleum, and industrial activities. Commercially H2S is 
mainly used to manufacture elemental sulfur and sulfuric acid, an important industrial 
product (Strickland, Cummings et al. 2003). Even in low concentrations, prolonged H2S 
exposure can have detrimental effects, and exposure to high concentrations can be fatal.  
Recently H2S has been discovered to be an endogenously produced gaseous 
signaling molecule and, as a result, is beginning to receive much attention as a possible 
therapeutic drug. A growing body of literature has increasingly recognized that H2S plays 




decade, H2S has been transformed from a poisonous gas into a marketable product with 
growing therapeutic potential for protecting the heart from ischemic disease. 
Property Information 
Molecular weight 34.08 
Color Colorless 
Taste Sweetish taste 
Physical state Gas (under normal ambient conditions) 
Melting point -85.49oC 
Boiling point -60.33oC 
Density in air 1.19 (air=1.00) 
Density at 0 oC, 
760mmHg 
1.5392g/L 











5.3 g/L at 10 oC; 4.1g/L at 20oC; 3.2 g/L at 30 oC 
Soluble in glycerol, gasoline, kerosene, carbon disulfide, crude 
oil 
Partition coefficients Not applicable 









at 20 oC 
at 30 oC 
at 40 oC 
 
468 atm/mole fraction 
600 atm/mole fraction 




Conversion factors 1ppm = 1.40 mg/m3 
Explosive limits Upper, 45.5%; lower, 4.3% (by volume in air) 





Dangers of H2S 
H2S exists primarily in a gaseous form, in which it is colorless, flammable, and 
has a pungent odor of rotten eggs. With a molecular weight of 34.08 grams, H2S is 
heavier than air and as such collects near the ground, often resulting in dangerous pockets 
where H2S concentrations reach high levels. H2S poisoning comes mainly through 
inhalation into the lungs, from which it spreads to the rest of the body. Oral 
administration of the solid sulfide salts has been used in studies, but no case of toxic 
effects in people ingesting H2S has been recorded (Beauchamp, Bus et al. 1984; Agency 
for Toxic Substances and Disease Registry 2006).  
H2S acts as an irritant at lower concentrations, burning the eyes, nose, and lungs; 
at higher concentrations, studies show that H2S affects the respiratory, nervous, and 
cardiovascular systems. Specifically, H2S was demonstrated to cause vacuolization, 
ciliocytophthoria, and nasal sloughing and lesions in the respiratory system at a 
concentration of 300 ppm (Lopez, Prior et al. 1987; Brenneman, James et al. 2000). In the 
brain, a multitude of effects were observed at a range of concentrations from 10 ppm to 
500 ppm, including inhibition of enzymes, such as carbonic anhydrase, to alterations in 
brain waves in the hippocampus. In the heart, rabbits exposed to 72 ppm H2S for 0.5 
hours for five days demonstrated arrhythmias for several days, while those exposed for 





Despite its toxic effects, H2S is actually produced in mammals as a signal 
molecule. H2S in the blood and tissues comes from the metabolic breakdown of the 
amino acid L-cysteine from two enzymes (cystathionine B-synthase and cystathionine 
Gam-lyase) found in virtually every organ of the body. C -synthase and 
cystathioni -synthase, which are responsible for the metabolism of L-cysteine, 
produce H2S in extremely low concentrations, on the order of picomoles per milligram of 
protein (Szabo 2007). Other H2S sources include microflora of intestinal epithelium and 
the inorganic reduction of elemental sulfur in erythrocytes (Szabo 2007). One of the 
fundamental questions that remains disputed is exactly how much H2S exists. Plasma 
concentrations of H2S have been reported in the range of 30 to 50 µM, though it varies 
significantly depending on experimental procedure (Szabo 2007; Furne, Saeed et al. 
2008). This issue is important in understanding the therapeutic mechanisms of H2S and 
their relationship to its physiological effects. At such low concentrations, H2S loses its 
cytotoxic properties and becomes cytoprotective instead, playing a role in regulating 
vasodilation, blood pressure, and smooth muscle contraction (Lefer 2007; Szabo 2007; 
Zhang, Huang et al. 2007). In micromolar concentrations, H2S also induces upregulation 
of anti-inflammatory genes. However, it appears that H2S levels must fall in a very 
specific concentration range for the molecule to retain its protective effects. If H2S 
concentration is too high, H2S regains its toxicity and becomes proinflammatory, while 
concentrations that are too low have been associated with heart disease (Szabo 2007). 
The discovery of these regulatory properties of H2S has led to increasing interest in the 




H2S and Ischemia-Reperfusion Injury 
Among the therapeutic applications of H2S of interest is reducing I/R injury, 
which represents a serious issue in organ transplantation. In several studies, H2S has been 
shown to reduce the damage from I/R when applied both pre-ischemia and post-ischemia. 
Pretreatment with administration of NaHS, a H2S donor, 15 minutes before myocardial 
ischemia has been shown to significantly reduce myocardial infarct size by 
approximately 26% (Sivarajah, McDonald et al. 2006). A later study confirmed an even 
greater cytoprotective effect when treatment with an H2S donor at the time of reperfusion, 
instead of before ischemia, significantly reduced myocardial infarct size by as much as 
72%, as revealed by triphenyltetrazolium chloride staining (Elrod, Calvert et al. 2007). 
The infarction-reducing effects in this study varied depending on the concentration of 
H2S; the maximum reduction of 72% was achieved with 50 g/kg (0.9 M) of the H2S 
donor (Elrod, Calvert et al. 2007). Other studies also support the idea of concentration-
dependent limitation of infarct size, but quote different optimal concentrations. For 
example, one study found the smallest percentage of infarction with a 1 M 
concentration of NaHS (Ji, Pang et al. 2008). In addition, this study also suggests an 
upper boundary to infarction limitation, as the 100 M concentration of NaHS did not 
significantly reduce infarction compared to the control (Sivarajah, McDonald et al. 2006). 
Furthermore, the cytoprotective effects of H2S are not limited to the aforementioned 
myocardial tissue. H2S has been shown to confer similar protection to intestinal, muscle, 
and cutaneous tissue (Weinstein, Henderson et al. 2009; Jimenez, Henderson et al. 2010).  
Research has suggested that H2S may play a role in regulating various 




the contraction of smooth muscle (Szabo 2007). However, many of H2
effects may occur only in low concentrations. In situations of heart disease, H2S levels 
are lower than in healthy hearts (Szabo 2007). Furthermore, micromolar concentrations 
of H2S help induce expression of anti-inflammatory or cytoprotective genes. 
However,H2S at higher concentrations has pro-inflammatory effects (Szabo 2007). H2S 
also regulates the gene for subunit V of cytochrome c oxidase, the terminal enzyme 
complex of the electron transport chain (Blackstone, Morrison et al. 2005). The proposed 
mechanism through which low concentrations of H2S reduce metabolic rates is inhibition 
of cytochrome c oxidase, which blocks oxygen uptake and prevents ATP production, 
effectively inducing a suspended-animation-like state in a mouse model (MacDonald and 
Storey 1999).  
The literature provides various experimental models and methods that have been 
developed to study H2S cardioprotection. Studies have measured the extent of myocyte 
injury to determine the effects of H2S. One way to measure myocyte injury is by using 
myocardial protein markers. Significantly reduced levels of a cardiac-specific isoform of 
troponin-I in hearts treated with 50 g/kg of the H2S donor confirmed the protective 
effect of H2S (Sivarajah, McDonald et al. 2006). Measurements showing a concentration-
dependent limitation of the release of creatine kinase, another protein marker, from 
coronary effluent also indicate the protective role of H2S (Szabo 2007). Another method 
of measuring myocyte injury is through the trypan blue exclusion assay (Bian, Yong et al. 
2006). One study found that the percentage of viable cells increased in a concentration-
dependent manner, with the greatest percentage of viable cells seen after ischemia in a 




ATP content is an important measurement of the protective effects of H2S since it 
is one of the best indicators of myocyte recovery (Hu, Li et al. 2007). Hearts treated with 
NaHS, an H2S donor, showed significantly higher levels of myocardial ATP following 
reperfusion (Hu, Li et al. 2007). As stated previously, H2S has been proven to lower the 
metabolic rate (Blackstone, Morrison et al. 2005). In return, this lowers the levels of 
2S reduces injury by 
reducing the need for high levels of O2.  
Isolated hearts treated with an H2S donor also tend to exhibit lower levels of 
apoptosis. TUNEL staining identified apoptotic cells with brown nuclear staining (Hu, Li 
et al. 2007). Although there is some amount of apoptosis in H2S-treated hearts, it is 
significantly reduced (Elrod, Calvert et al. 2007). In some cases, H2S-treated hearts were 
found to have a 59% reduction in the number of apoptotic cells (Hu, Li et al. 2007; 
Zhang, Huang et al. 2007).  
Although many studies have shown that H2S is able to reduce I/R injury, the 
mechanism by which H2S acts is not well understood. However, researchers have pointed 
to the mitochondria, and in particular, relationships between ROS, calcium, and 
metabolism, to elucidate the mechanisms of H2S cardioprotection. As described 
previously, ischemia-reperfusion (I/R) injury is the biphasic damage that tissues undergo 
during periods of metabolic stress due to low blood flow and oxygen, followed by 
oxidative stress accompanying re-oxygenation. Important to the progression of injury 
during ischemia is the role of calcium. Calcium loading occurs as the acidic environment 
leads to high Na+ concentration, which in turn is exchanged for calcium via a membrane 




environments; these and other calcium-activated enzymes destroy proteins or lipid 
membranes, making the cell more susceptible to rupture (Murphy and Steenbergen 2008). 
Lactate and other metabolic byproducts build up as the organ uses anaerobic metabolism 
to support basic homeostatic processes (like the sodium-potassium pump) in the low-
oxygen preservation solution. Upon reperfusion, these byproducts fuel the generation of 
ROS, which directly damage cellular structures (Jamieson and Friend 2008). 
The mitochondrion is a site of particular interest as it plays a critical role in 
mediating I/R injury. A substantial portion of damage to the electron transport chain 
(ETC) occurs during ischemia. ROS are generated due to inefficient electron transfers, 
and these can further damage the ETC, leading to further ROS generation in a dangerous 
feedback cycle (Roth and Nystul 2005). Due to membrane disruption in the mitochondria 
by ROS, cytochrome c is also released, which leads to the activation of caspases and 
apoptotic pathways (Chen, Camara et al. 2007). The membrane transition pore (MTP) is a 
non-specific channel in the inner mitochondrial membrane that opens under conditions of 
high matrix calcium and ROS, conditions that occur during the start of reperfusion 
(Murphy and Steenbergen 2008). The opening of the MTP leads to the dissipation of the 
proton gradient and the inability of mitochondria to make ATP, which leads to cell death. 
Thus, the extent to which the MTP opens determines the extent of reperfusion injury. The 
most effective therapeutic measures, such as ischemic preconditioning, thus target the 
events during ischemia that set the stage for MTP opening, including high Ca2+ loading 
and ROS production (Halestrap, Clarke et al. 2007). 
In this context, H2S cardioprotection can be explained by mechanisms that inhibit 




on H2S in hearts focuses on ATP-activated potassium channels as the main mechanism of 
the cytoprotective influence of H2S. Several studies show that the introduction of 
glibenclamide, a selective K-ATP channel blocker, blocks the protective effects of H2S 
(Hu, Li et al. 2007; Zhang, Huang et al. 2007). For example, mitochondrial K-ATP 
channels were implicated in this mechanism by blocking the channels with 5-
hydroxydecanoate and observing the subsequent protective effects of H2S (Sivarajah, 
McDonald et al. 2006; Ji, Pang et al. 2008). The activation of mitochondrial K-ATP 
channels in particular is believed to confer protection during ischemia, and so would be 
beneficial for scenarios like organ storage. The opening of these channels increases the 
potassium influx to the mitochondria, which lowers the membrane potential. As calcium 
uptake depends on this membrane potential, mitochondrial K-ATP channels contribute to 
preventing calcium overload (Halestrap, Clarke et al. 2007). In addition, H2S itself is a 
potent antioxidant, and either directly scavenges free radicals or signals intracellular 
antioxidant defenses (Szabo 2007). H2S has been shown to trigger multiple anti-apoptotic 
and antioxidant pathways (Jha, Calvert et al. 2008). The targets for these pathways 
include: GSH, HO-1 (intracellular antioxidants), HSP-90, and Bcl-2 (anti-apoptotic 
agents) (Szabo 2007; Bliksoen, Kaljusto et al. 2008; Jha, Calvert et al. 2008). Finally, and 
perhaps most interestingly, H2S is capable of suppressing metabolic activity. 
Suspended Animation 
The inhibition of cytochrome c oxidase to block oxygen uptake and prevent ATP 
production is another proposed mechanism by which H2S at low concentrations reduces 
metabolic rates and core body temperature, as low concentrations of H2S effectively 




2005). When mice breathed 150 ppm H2S for 20 minutes, they entered a hypometabolic 
state that allowed them to survive hypoxic conditions for more than six hours. Without 
H2S pretreatment, mice could only survive for 15 minutes (Blackstone and Roth 2007). It 
is unclear how this adaptive response specifically operates (Cooper and Brown 2008). 
However, other researchers have explored blocking the ETC during ischemia as a means 
of protecting the mitochondria from ROS-mediated injury (Chen, Camara et al. 2007). By 
mild uncoupling of the ETC with pharmacological agents, the researchers observed lower 
mitochondrial potential, which is correlated with ROS-production during ischemia.  
Metabolic reduction is expected to allow cells to survive low-oxygen conditions 
(Roth and Nystul 2005; Blackstone and Roth 2007). Hibernation, an example of a 
suspended animation state utilized by many animals, can protect organs through 
hypometabolism, by which 88% of energy is saved that would otherwise be expended in 
maintaining euthermic processes (MacDonald and Storey 1999). Hypometabolism is 
achieved through active controls that coordinate a strong suppression of both ATP-
consuming and ATP-generating processes, prioritizing ATP consumption to sustain vital 
processes (Storey 1997). In addition, genes controlled by hypoxia-inducible factor alpha 
(HIF- ) are up-regulated in hibernation (Storey 1997). HIF-  helps control a range of 
cytoprotective responses, including red blood cell proliferation and activation of HO-1 
(Bernhardt, Campean et al. 2006). 
H2S and Organ Preservation 
As hibernation can increase resistance to hypoxic and ischemic insults, the 
protective effects of H2S have been investigated in the context of transplantable organs. 




Although these studies differ in methodologies and experimental protocols, (such as 
variations in time of ischemia, time of reperfusion, and pre- or post-conditioning) they 
share several common elements. For example, most studies use a Langendorff perfusion 
column to perfuse the heart and measure overall function of the heart by monitoring 
various parameters such as coronary flow, coronary perfusion pressure, heart rate, 
temperature, and myocardial electrogram. Many studies also use NaHS in solution as an 
H2S donor to deliver H2S into the cardiac tissue (Ji, Pang et al. 2008). In addition, the 
research focuses on certain widely accepted indicators of myocardial injury or recovery, 
such as left ventricular function, infarct size, creatine kinase markers, ATP content, and 
apoptosis levels. Some studies have shown that NaHS treatments improve left ventricular 
developed pressure (LVDP) after reperfusion (Sivarajah, McDonald et al. 2006; Hu, Li et 
al. 2007; Zhang, Huang et al. 2007). 
As previously mentioned, H2S has many cardioprotective properties that should 
protect the organ from I/R injury in the context of organ preservation. One of the few 
studies that have ventured to apply H2S to whole organ preservation was conducted by 
-Henseleit (KH) buffer, 
and submerged hearts in this solution for six hours. For comparison, hearts were also 
submerged in a control group (KH buffer without NaHS) and St. Thomas solution (a 
cardioplegic solution). Afterwards, they tested ATP content, apoptosis index, and heart 
performance. The hearts submerged in NaHS had the highest ATP content, lowest 
apoptosis index, and performed equally well as hearts preserved in St. Thomas solution. 
Adding a K-ATP channel blocker (glibenclamide) to the NaHS solution erased the 




ATP channels and lowered Ca2+ accumulation. Other possible mechanism of H2S 
protection include ROS scavenging, vasorelaxation at reperfusion, and lowering 
metabolism by promoting a state of suspended animation (Hu, Li et al. 2007). 
E ffect of Timing on Treatment 
 effects may be divided into two categories: direct effects and 
signaling effects. Direct effects depend on the presence of the molecule as an effector for 
the protective mechanism. These include chemical modification of K-ATP channels and 
scavenging of ROS. In addition, H2S is a trigger or mediator of multiple anti-apoptotic 
and antioxidant signaling pathways. Thus, the protective effects do not require the 
continued presence of the molecule, only an amount that begins and sustains the signaling 
cascade. The question of how best to administer H2S (as a bolus injection or through 
continuous infusion) is closely related to the question of which type of effect is dominant 
in cardioprotection (Osipov, Robich et al. 2009).  
There is convincing evidence for both types of effects. In vitro tissue studies 
adding NaHS to an ROS-generating system strongly support the notion of a direct ROS-
scavenging effect (Geng, Chang et al. 2004). H2S is thought also to directly open K-ATP 
channels, and there is evidence that it can do so by chemically reducing the cysteine 
residues on that protein. This theory is supported by the loss of H2S stimulatory effect on 
K-ATP channels observed when point mutations are introduced at the cysteine residues 
(Jiang, Tang et al. 2010). In whole-cell patch clamp experiments, the hyperpolarization 
induced by H2S was reversed by removing H2S from the bathing solution (Tang, Wu et 
al. 2005). While K-ATP channels are generally thought to be an important signaling 




raising mitochondrial membrane potential and lowering calcium uptake (Yellon and 
Downey 2003). If this were true, then sustained concentrations of H2S would be 
important for preconditioning protection. Finally, H2S inhibits mitochondria and slows O2 
reduction by out-competing oxygen at moderate concentrations (above 50-
NaHS) and binding to cytochrome c on the ETC (Cooper and Brown 2008). As explained 
previously, this inhibitory effect on oxidative respiration is proposed to be cytoprotective 
by reducing ROS generation during the ischemic period (Roth and Nystul 2005; 
Blackstone and Roth 2007). The process can be reversed with sufficient oxygen 
(Collman, Ghosh et al. 2009). Interestingly, it has been found that a continuous infusion 
of NaHS solution is necessary to induce metabolic reduction in a porcine model, while 
bolus injection fails to do so (Simon, Giudici et al. 2008). On the other hand, it has been 
observed that mice breathing 150 ppm H2S for 20 minutes entered a hypometabolic state 
that allowed them to survive in low-oxygen environments without additional H2S for 
more than 6 hours after the pretreatment (Blackstone and Roth 2007). Clearly, there is 
still much research to be done to determine what effect the duration of exposure to H2S 
has on the protection it confers (Osipov, Robich et al. 2009; Wagner, Asfar et al. 2009). 
As previously explained, H2S has been used as a preconditioning stimulus to 
protect the heart from simulated I/R injury, either through an initial bolus injection 
(Sivarajah, McDonald et al. 2006) or through brief periods of alternating perfusion with 
NaHS and buffer solution (Pan, Feng et al. 2006). H2S has been shown to up-regulate 
several antioxidant genes including HO-1 and trigger anti-apoptotic pathways (Jha, 
Calvert et al. 2008; Calvert, Jha et al. 2009). However, similar to classical ischemic 




window. Using cardiomyocytes, one group observed this window of protection to be 1-3 
hours after treatment (Pan, Feng et al. 2006). This window of protection is inadequate to 
protect the organ during preservation periods that ideally would greatly exceed four 
hours. The reason for the decay in the activation of these signaling pathways remains 
unclear. Interestingly, attempts to translate classical ischemic preconditioning to organ 
preservation have met limited success, and some have pointed to the time restrictions of 
the early window of protection as a possible explanation (Huang, Shan et al. 2009). 
One of the complicating factors to understanding the mechanisms behind H2S 
effects lies in its transient nature. As a small molecule, it is highly volatile and can easily 
escape from solution. For this reason, most researchers prefer to prepare the solution no 
more than 3 days ahead of the experiment (Dombkowski, Russell et al. 2004). The rate of 
H2S release likely has a profound effect on the physiological response as shown by a 
study that investigated the vasorelaxation on rat aortic rings using a slow-release H2S 
drug (GYY4137) and NaHS, a fast H2S donor (Li, Whiteman et al. 2008). The slow-
release drug gave a sustained relaxation effect while the fast-release drug induced rapid, 
transient relaxation (Li, Whiteman et al. 2008). Another possible mechanism for H2S 
depletion could come from the fast metabolism of H2S by mitochondria, despite the low 
oxygen concentrations and cold temperatures found in preservation solutions. The 






Drug Delivery and its E ffects on the Heart 
There have been many developments in methods to treat diseased or damaged 
heart and cardiac tissues. Many of these recent advancements have focused on targeted 
drug delivery directly to these tissues, in contrast to oral or intravenous drug delivery. 
The efficacy of targeted drug delivery is dependent on the discovery of novel biomarkers 
that are up-regulated or uniquely expressed in such diseased tissues (Scott, Crabbe et al. 
2008). Studies in recent years have demonstrated that bio-derived materials also improve 
cardiac function after implantation due to their angiogenic potential (Jiang, Wang et al. 
2009). 
One method of targeted drug delivery to the heart is through direct injection. 
Direct myocardial injection of therapeutic agents for the purpose of myocardial 
revascularization was explored nearly a decade ago as a feasible and safe alternative to 
surgical-based injection procedures, or open heart surgery (Kornowski, Fuchs et al. 
1999). Direct injection can be administered to the peri-infarct myocardium or into the 
vasculature. For example, direct injection of an adenoviral vector that codes for heat 
shock protein 70 (HSP70) was able to restore post-infarct heart function in rats when 
administered as a pretreatment (Lau, Griffin et al. 2000). Other studies have shown that 
direct injection of a vector coding for human growth hormone can be effective in 
improving post-infarct cardiac function as well (Scott, Crabbe et al. 2008). 
Intramyocardial injection of skeletal myoblasts has also been shown to treat post-
infarction chronic heart failures, particularly via the route of retrograde intracoronary 




Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(VEGF) are both molecular signaling factors that also have cardioprotective properties. 
Direct injection of the gene for VEGF has been shown to stimulate angiogenesis, and is 
thought to induce the growth of functional vasculature after an infarction when delivered 
in conjunction with complementary compounds for angiogenesis such as angiopoietin-1, 
RhoA, and Rac1. Another study showed that injection of hydrogel microspheres 
containing bFGF into a peri-infarct region was able to improve left ventricular function 
and increase blood vessel density (Scott, Crabbe et al. 2008). Furthermore, studies show 
that bFGF-induced angiogenesis with cardiomyocyte transplantation is a promising 
procedure for myocardial infarctions (Freiberg and Zhu 2004). 
Targeted Drug Delivery to the Heart 
Targeted drug delivery can be accomplished with the aid of new developments in 
drug delivery vehicles, such as liposomes, polymeric micelles, and biodegradable 
nanoparticles. An ideal vehicle for drug delivery should be non-toxic, biocompatible, 
non-immunogenic and biodegradable (Scott, Crabbe et al. 2008). 
Two main considerations in drug delivery to the heart tissues are the vehicles 
delivering drugs or treatment, and the identification of biomarkers to be targeted by these 
treatments. Other important considerations are the release rates afforded by these drug 
delivery vehicles and the specificity of the targeting. Drug release can be initiated by 
external energy sources, while specificity can be fine-tuned by modified drug delivery 
vehicles, such as ligand-coated drug carriers or the use of antibody targeting. These 
methods and similar approaches have advantages, but largely remain imperfect. For 




and diseased tissue (depending on the target chosen). In order for biomarkers to be 
effective, a drastic up-regulation in diseased tissue would be ideal. Appropriate biological 
targets, however, have yet to be discovered for many types of treatments (Scott, Crabbe 
et al. 2008). 
One drug delivery method that has received significant attention has been 
hydrogels. Hydrogels are networks of crosslinked hydrophilic polymers. They have been 
found to be particularly successful in drug delivery due to their biocompatibility and 
ability for sustained release. The polymers that comprise hydrogels for biomedical 
applications are often specifically chosen because these base polymers already have little 
immunological reactions. For example, to enhance biocompatibility, many polymer 
microspheres are constructed from materials derived from natural polymers (such as 
algae and chitin) or by the employment of polymers made from naturally present 
monomers such as lactic and glycolic acids. Conversely, to enhance mechanical 
properties of the gel, these polymers may be co-polymerized with other polymers such as 
polyethylene. Also, as a result of its hydrophilic nature, hydrogels are largely water 
volume wise. This creates a microenvironment very similar to other soft tissue.  
Hydrogels are also of great interest in biomedical applications because of their 
versatility. External stimuli, such as pH, temperature, antigens, electric fields and 
upon the composition of the polymer. This can allow for the introduction of materials, 
drugs, or signaling factors into specific organs, tissues or body cavities with greater ease. 




infarcted myocardium has been shown to preserve left ventricular heart function by 
preventing systolic bulging (Jiang, Wang et al. 2009). 
Polymer microspheres are drug delivery vehicles that can be sustainably rate-
controlled and designed to be target specific, as opposed to exposing the whole body to a 
drug. Microsphere delivery of therapeutics also prevents the variance in drug levels that 
is inherent to oral drug delivery. Hydrogels accomplish this sustained delivery via two 
main mechanisms: either the diffusion of the drug through the crosslinked polymer, or via 
degradation of the polymer matrix, releasing the drug to the environment. Various 
properties of polymer microspheres can affect the desired release rate, including the 
molecular weight of the polymer used, the distribution of the drug to be delivered within 
the microsphere, polymer blending, crystallinity, microsphere size, porosity of the 
hydrogel, physical distribution of the microspheres in the target area, and the individual 
morphology of the spheres. Microspheres composed of more than one polymer can have 
a unique release profile based on the degradation rate and other properties of each 
polymer in the blend, as well the composition percentage of each of the polymers 
(Freiberg and Zhu 2004).  
Although a common aim for a drug release profile is constant release rate over 
time, often times this desired release profile is not achieved. The most common drug 
release profiles exhibit an initial spike in concentration of expelled drug or medication 
from the sphere or a usually more constant drug delivery profile dependent on diffusion 
and degradation. There are additional strategies to trigger release upon encountering a 




forming a biocompatible polymer that can be triggered through a change in pH, 
temperature, or antigens, localized and specific drug delivery can be accomplished.  
Microspheres prepared from monomers can be polymerized by emulsion, 
suspension or dispersion techniques, and can be formed on the nanometer-size scale. 
Microspheres can also be prepared from the polymerization of linear polymers, many of 
which are available commercially (Freiberg and Zhu 2004). 
Method of Delivery 
Gelatin hydrogel microspheres (GHMs) have been used as a novel non-viral agent 
for gene delivery (Kushibiki and Tabata 2004). They can be delivered via catheter-based 
injection, a novel technique compared to the only previous option, delivery via open-
chest surgical technique. One study examined three routes of injection: anterograde 
injection (AI) via coronary arteries, retrograde injection (RI) via coronary veins, and 
direct myocardial injection (DI) via the coronary sinus. A catheter-based strategy of drug 
AI distributed 
microspheres homogeneously and broadly through the target area with a 73±11% 
retention. However, microinfarctions were detected, which most likely caused a lack of 
increase in coronary flow reserve. RI proved to have the lowest efficacy of the three 
delivery strategies but was still efficient nonetheless; only 22± 8% of the microspheres 
were retained and spread homogenously. The retention may have been affected in part by 
the timing of the injection. Lastly, DI was tested without any fatal events and resulted in a 
47±14% retention rate in the heart, while the rest leaked to the lungs from the puncture 
site. Overall, the results suggest that RI and DI are effective delivery strategies while AI 




Microspheres prove to be particularly versatile as drug delivery vehicles. GHMs 
are larger than viral vectors. As discussed in a previously mentioned study, the type of 
injection affected the spread of microspheres (Hoshino, Kimura et al. 2006). In addition, 
there are other factors that must be considered before GHMs are used as drug delivery 
vehicles. In particular, GHMs can aggregate after being suspended, with microspheres 
that average 10 m in size being able to form clusters over 20 m in size. Despite the 
effectiveness of AI when used for viral vector-based gene therapy, the occurrence of 
microinfarctions and micro-embolisms makes the use of GHMs with AI unsuitable for 
the heart. Furthermore, when microspheres were used in a clinical setting, the 
microspheres injected with RI or DI leaked out from the heart via the coronary sinus and 
likely became trapped in the lungs. (Hoshino, Kimura et al. 2006). 
In particular, GHMs can carry genes, proteins, or therapeutic agents such as H2S, 
which can be released gradually over an extended period of time. In addition to its ability 
to distribute, GHMs are very versatile due to their ability to be varied in diameters of 1 
m to greater than 100 m, or even sheets. Additionally, gelatin has already been 
established as a compound safe for clinical use. GHMs containing bFGF were used with 
an ischemic cardiomyopathy model, along with cardiomyocyte transplantation. GHMs 
were able to effectively provide controlled release of bFGF. In doing so, the 
microspheres created an environment suitable for the survival and activity of transplanted 
cells and thus enhanced bFGF-induced angiogenesis (Yamamoto, Sakakibara et al. 2003).  
Based on prior studies, it would appear that while many polymer fabrication 
methods may be available, a favorable biomaterial for the particular study of delivery of 




study on different injections methods, the most favorable  method of delivery would be 






The gelatin (Type A, from porcine skin) and glutaraldehyde (50% photographic 
grade) were obtained from Sigma-Aldrich. Tween 20 (enzyme grade) was purchased 
from Fisher-Scientific. Sodium hydrosulfide hydrate (NaHS) was purchased from Sigma-
Aldrich. The ATP assay was purchased from Abcam, and a Caspase-3 Assay kit was 
obtained from BD Pharmingen. The cell line was obtained from ATCC and Dulbecco's 
Modified Eagle Medium (DMEM) was purchased from Invitrogen. All reagents utilized 
were used as received. For immunohistochemistry, biotin-conjugated goat anti-rabbit IgG 




Gelatin microspheres were fabricated with Type A gelatin from porcine skin. 0.26 
g of gelatin was fully dissolved in 5.0 mL of distilled water, and heated to 50°C in a 
water bath. The dissolved gelatin was sprayed with an atomizer into 50mL of vegetable 
oil, previously heated to 50°C and stirred at 1150 rpm. The gelatin-oil solution was stored 
at 4°C and stirred at 1150 rpm for 30 minutes before 20mL of acetone was added and the 
solution was left to stir for another hour. Solution was transferred to 50 mL Falcon tubes 
and centrifuged for 5 minutes at 4000 rpm to isolate the microspheres after decanting the 
supernatant. Microspheres were transferred to microcentrifuge tubes. 1mL acetone was 




supernatant was decanted and 0.5 mL isopropyl alcohol was added to each tube. After 
centrifuging for 5 min at 4000 rpm, the supernatant was decanted and the microspheres 
were stored at 4°C. All reagent volumes were scaled up linearly for fabricating larger 
quantities of microspheres. 
The fabricated microspheres were imaged on an Axiovert 40CFL inverted light 
microscope (Zeiss). The sizes of the microspheres in the image were measured using 
SPOT (Diagnostic Instruments), a calibrated image analysis program. These sizes were 
recorded and reported as mean ± standard deviation. 
Crosslinking Microspheres 
Gelatin microspheres were crosslinked with glutaraldehyde after fabrication. 100 
mg microspheres were mixed into a beaker with 100 mL of the desired glutaraldehyde 
solution (1M or 4.75M) and 100 mg Tween 20 and stirred at 1150 rpm at 4°C for 15 
hours. The solution was transferred to 50 mL Falcon tubes and centrifuged for 5 minutes 
at 4000 rpm to isolate the microspheres after decanting the supernatant. Microspheres 
were transferred to a beaker with 2 mL 0.5M glycine and 23 mL distilled water and 
stirred at 37°C for 1 hour. The microspheres were centrifuged a second time and distilled 
water was added to wash the microspheres before air-drying. 
Microsphere Loading 
NaHS solution was prepared by dissolving sodium hydrosulfide hydrate (NaHS 




Microsphere Release Profile 
Microspheres loaded with NaHS solution overnight were centrifuged at 5000 rpm 
for 1 min at room temperature. The loading solution was removed and 2 mL PBS was 
added to microspheres to rinse away residual amounts of loading solution. Microspheres 
were centrifuged again and supernatant was decanted. Microspheres were then rinsed for 
a second time before 2 mL PBS were added to the tube of microspheres and the timer 
was started.  
Zinc Acetate Assay 
The concentration of H2S released from the microspheres into the surrounding 
solution was evaluated by the zinc acetate assay. At each time point of 0, 15, 30, 60, 120, 
180, 240, 300, 360 min, 50 µl of the solution was removed from the microspheres tube 
and added to a tube of 250 µl zinc acetate (1% w/v) and 450 µl of water. 50 µl PBS were 
added back into the tube of microspheres to replace the previously removed volume. 
After 7 min, 133 µl of N, N-dimethyl-p-phenylenediamine sulphate (DMPPDA; 20µM) 
and 133 µl of FeCl3(30 µM) were added to the tube with zinc acetate and 50 µl of 
sample. After 45 min, 250 µl of sample were added to a 96-well plate and the absorbance 
was measured by a spectrophotometer at 670nm. 
Cell culture 
Murine cell line (H9c2) cardiomyocytes were cultured in 88% high glucose D-
MEM supplemented with 10% (volume fraction) fetal bovine serum, 1% sodium 





Media was changed every 2-3 days and cells were passaged at 80% confluence. 
At 80% confluence, old media was aspirated. 1 mL trypsin-EDTA was added and the 
flask was rocked to coat the surface and the trypsin was aspirated. 3 mL of trypsin-EDTA 
was added and cells were incubated at 37°C for 5 min. Cells were then checked under 
microscope to ensure they had been lifted from the surface. Cells were mixed to break 
cell clumps, and then placed in Falcon tube containing 12 mL of media with 10% fetal 
bovine serum, and centrifuged. The supernatant, which contained the excess media, was 
then removed and an additional 12 mL of media was added and cells were resuspended. 
Cells were seeded onto 6-well plates at density of 1.0 x 104 cells per cm2. They were 
tested after they had grown to 90-100% confluence after two days. 3mL growth medium 
with 1x104 cells/mL were added to each well of the plate. The final seeding density was 
1x104 cells/cm2. 
NaHS in Cell Culture 
hydrosulfide hydrate (NaHS salt) in deionized water. 2
added to seeded wells of a 6-well plate containing 3 mL growth media and cells. The 
concentration of H2S in solution was evaluated by the zinc acetate assay at each time 
point of 0, 15, 30, and 60 min. Controls of NaHS loaded microspheres in media without 
cells was also evaluated by the zinc acetate assay at each time point. Absorbance was 
read by a spectrophotometer at 670nm. 
Microsphere Release profile in Cell Culture 
6-well cell culture plates were pre-seeded with murine cell line (H9c2) 




NaHS solution. 50mg, 100mg, or 250mg of H2S-loaded microspheres were placed in the 
pre-seeded 6-well cell culture plates for 0, 15, 30, 60 min. At each time point, 50 µl of the 
media solution was removed from the well and added to a tube of 250 µl zinc acetate and 
450 µl of water. After 7 min, 133 µl of DMPPDA and 133 µl of FeCl3 were added to the 
tube with zinc acetate and 50 µl of sample. After 45 min, 250 µl of sample were added to 
a 96-well plate and the absorbance was measured by a spectrophotometer at 670nm. 
Quantitative Viability Assay 
A mixture of 12 mL PBS, 12 µl Calcein, and 12 µl ethidium homodimer was 
prepared. The wells were rinsed with PBS and aspirated. 1 mL of the imaging solution 
was added to each seeded well of a 6-well plate. The well plates were incubated in the 
dark for 30 min. The center of each well was imaged and the dead cells were counted. 
Metabolic Activity Assay 
The 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a 
yellow tetrazole (MTT) assay solution was prepared using MTT reagent and PBS. Media 
from each well of the seeded 6-well plate was aspirated off and the wells were rinsed 
with 1 mL PBS before PBS was removed. 900 µl of PBS and 100 µl of MTT solution 
were added to each well. The cell culture was incubated at room temperature for 3 hours. 
900 µl of MTT stabilizing solution was added to each well. Wells were gently and 
uniformly shaken in the gyratory shaker and the solution in each well was pipetted up and 
down to ensure dissolution of crystals. 200 µl of the solution in each well was transferred 
to a 96-well plate and a spectrophotometer was used to measure the absorbance at 570 





Ex V ivo Model 
Selection of an Animal Model 
In order for our findings to have significance for organ transplantations in clinical 
settings, the study must be carried out in an animal model with comparable anatomy. The 
four-chambered heart of a rat is analogous to the four-chambered hearts of humans and 
other mammals, whereas fish have two-chambered hearts that are not comparable in 
structure. Although there are species of invertebrates with hearts, they are not analogous 
to our circulatory system, and experimentation on the hearts of such species would not 
produce significant results. The possibility of using mice as a model was also 
investigated, but determined to be unfeasible. The small size of mice equates to a 
miniscule heart, which would be very difficult for the surgical team to manipulate. 
Additionally, this small size makes it impossible to retrieve enough tissue for all of the 
planned assays at all the time points from a single heart. 
Various databases were searched in order to find alternatives to animal testing, 
ll eleven results from both 
searches were critically analyzed for their relevance to our study. Of the eight hits from 
the Pubmed search, three of the articles discussed xenotransplantation as an alternative to 
heart transplantation. Since our study does not encompass organ transplantation, but only 
organ extraction and the ex vivo time period, these articles are not relevant. Three more 
articles discussed surgical procedures to treat heart problems in the patient, which is 
unrelated to the storage of harvested organs. Another article proposed a method of 
keeping an excised heart beating, which already assumes animal testing and therefore 




be eliminated through tissue engineering of accurate models, admits that such technology 
is not yet fully developed. Of the results obtained through Altweb, one merely discusses 
the potential for alternatives to animal experimentation but does not offer specific 
suggestions. The second and third are chapters from a handbook on humane experimental 
techniques and is not specific to alternatives to excising animal hearts for 
experimentation. In addition, a second search was performed using different search terms. 
two hits. One hit concerned alternatives to electroejaculation of bulls, and the other 
discussed aortic valve replacement with homografts, neither of which was relevant to our 
study. 
Our project seeks to investigate a novel storage method to preserve isolated 
hearts. The heart is a complex organ whose functionality following storage can be 
influenced by various factors, such as metabolic rate, myocardial infarctions, and the 
buildup of reactive oxidative species. Computer models are not yet powerful enough to 
make accurate predictions for heart viability following our novel storage method because 
they cannot adequately account for all of the factors affecting heart viability. In addition, 
our proposed method focuses on the effects of H2S, a compound that has only recently 
been investigated for its potential to preserve isolated tissues. Thus, its mechanism of 
action is still under debate and therefore cannot be represented in computer or 
mathematical models. Similarly, the novelty of H2S, as well as the hydrogel method of 
delivery, requires experimentation in actual tissue in order to gather applicable data. 
Furthermore, due to the complexity of the heart, experimentation in cell cultures cannot 




viability require the whole organ. For example, measuring left ventricular developed 
pressure (LVDP) requires a heart and cannot be determined from a cell culture.  
To successfully evaluate the efficacy of using H2S to prolong heart storage, an 
animal model must be used because of the complex interactions in the heart that cannot 
be modeled by computer models due to lack of information on the H2S mechanism. As 
previously stated, the appropriate animal model must have similar anatomy to the human 
heart and feasible to experiment on. The model that fits this criteria and will contribute to 
a better understanding of how H2S will interact with cardiac tissue is a rat heart. Thus, a 
rat heart model will be used for the in vivo experiments. 
Surgery Methods 
The appropriate sample size for the comparison of two means from independent 
groups of rat hearts was calculated using the formula n  2K 2/ 2, where K represents a 
constant that can be chosen for a given power,  represents the standard deviation or 
variance in a given group, and  represents the difference between groups. (Daly, Bourke 
et al. 2000). For a 5% confidence level to detect a treatment effect of 95%, we used a K 
constant of 13.0. Based upon ATP values (Hu, Li et al. 2007), there was an expected 
difference of 150 µg/g and standard deviation of 50 µg/g. This calculation results in a 
sample size greater than or equal to 2.89, which was  rounded to n = 3 for the in vivo 
biopsy study. A rat heart submerged in UW solution will serve as a control. The 
experimental groups included a rat heart submerged in UW and NaHS solution, a heart 
submerged in UW solution with NaHS and H2S-loaded microspheres, and a heart 




The rat heart submerged in UW solution with NaHS will function as a standard to 
which the effects of the microsphere therapy will be compared. This is the group that will 
test the therapeutic effects of sustained levels of H2S in comparison to clinical standards 
and previous findings. A single heart submerged in UW solution with NaHS will be 
compared to a single heart submerged in UW solution with NaHS and PBS-loaded 
microspheres. 
 
F igure I I I-2: The four groups of the in vivo studies. The groups are a rat heart submerged in UW solution 
(clinical standard); rat heart submerged in NaHS+UW solution (control); rat heart submerged in UW 
solution with NaHS loaded microspheres (experimental); and finally, rat heart submerged in UW solution 






The anesthetic mix consisted of 1ml ketamine (100mg/mL), 0.1ml xylazine 
(100ng/mL), and 8.9ml sterile saline. Sprague-Dawley rats were anesthetized with the 
anesthetic mix (0.1mL/10g body weight). Hair was removed from the surgical site using 
clippers and the site was cleaned with 2 alternating scrubs of betadine soap and 70% 
alcohol using a sterile Q tip to remove the scrub without causing excessive heat loss due 
to alcohol evaporation. After an abdominal midline incision, the inferior vena cava 
(VCI) is isolated from surrounding tissue. 100 units of heparin were then injected into the 
VCI using a 30G needle. After waiting for 2 minutes for heparin to circulate, the rat was 
exsanguinated by cutting the infrarenal vessels. The thorax was quickly opened with a 
midline sternotomy and the pericardium was opened. Ice cooled saline (0.9%) was 
dripped onto the heart using a 10ml syringe. This was continued until the end of the 
harvest. The ascending aorta and the pulmonary trunk was dissected and separated. The 
distal ascending aorta was ligated with 6-0 silk. Cardioplegia (UW solution) was then 
injected into the proximal ascending aorta with a 30G needle (5-10ml over ~1 minute). 
The ascending aorta was then cut at the ligation, and the VCI and superior vena cava 
(VCS) were independently ligated with 6-0 silk. The pulmonary veins were then mass 
ligated using 6-0 silk and cut distal to the ligation. 
Histology 
Tissue F ixation and Slicing 
Following the storage protocol, hearts were biopsied and frozen in OCT (optimal 




thickness on a Cryostat (Microm HM550, Thermo Scientific), mounted on pre-cleaned 
Superfrost Plus slides (Fisher Scientific), and stored at -80 C. 
ATP Assay 
The ATP content of rat heart tissue samples was measured using the ATP 
protocol was followed with the addition of deproteinizing and neutralizing steps, as 
outlined below.  
Standard Preparation 
10 l of ATP Standard, provided with the kit, was diluted with 90 l of dH2O to 
yield 1 mM of ATP Standard. This standard was further diluted in a 1:50 ratio with dH2O 
for the fluorometric assay. 0, 2, 4, 6, 8, and 10 l of the more dilute solution was added 
into respective wells and the volume of each well was adjusted to 50 l/well with ATP 
Assay Buffer, provided with the kit, to yield 0, 0.4, 0.8, 0.12, 0.16, 0.2 nmol/well of ATP 
standard. 
Sample Preparation 
Biopsies of the left ventricle from each rat heart were transported in liquid 
nitrogen and stored at -80 C immediately following the storage protocol. Approximately 
10 mg of each sample was then weighed into a microcentrifuge tube. Throughout the 
following steps, samples were kept on ice as much as possible. Each sample was 
homogenized in 600 l of ATP Assay Buffer using a pestle (Fisher Scientific) for at least 
30 strokes. Samples were then centrifuged at 13,000 rcf at 4 C for 30 seconds to pellet 




fresh microcentrifuge tubes, and 100 l of ice-cold 2N perchloric acid was added. 
Samples were vortexed briefly to mix well, and placed on ice for 5 minutes to allow 
deproteinization. Samples were then centrifuged at 13,000 rcf at 4 C for 2 minutes to 
pellet precipitated proteins. 480 l of the supernatant from each sample was then 
transferred to fresh microcentrifuge tubes and frozen at -80 C for up to a month.  
ATP Detection 
When ready for analysis, the frozen samples were thawed slowly on ice. Once 
liquid again, the samples were centrifuged at 13,000 rcf at 4 C for 2 minutes to further 
pellet any protein precipitation. 120 l of each sample was then transferred to fresh tubes, 
and 5 l of ice-cold Neutralization Solution containing 5M KOH and 3M KHCO3 was 
added to neutralize the samples and precipitate excess perchloric acid. Samples were 
vortexed briefly to mix well and placed on ice for 5 minutes, after which samples were 
centrifuged at 13,000 rcf at 4 C for 1 minute. 40 l of the supernatant from each sample 
was added to a well in a 96-well plate and the final volume was brought up to 50 l/well 
with ATP assay buffer.  
50 l of Reaction Mix, containing 45.8 l of ATP Assay Buffer, 0.2 l of ATP 
Probe, 2 l of ATP Converter and 2 l of ATP Developer, all solutions provided with the 
kit, were added to each well of ATP Standard and sample before mixing and incubating 
at room temperature for 30 minutes, wrapped in foil. The signal was stable for 2 hours. 
Fluorescence was measured with excitation and emission wavelengths of 535 nm and 587 




ATP Content Calculation 
To calculate the ATP concentration, the 0 ATP Standard value was first 
subtracted from all standard and sample readings in order to correct for the background. 
The standard curve was then plotted. The total amount of ATP in a sample, Ts, was then 
calculated in nmols by applying the ATP sample reading, minus the 0 ATP Standard 
reading, to the standard curve. ATP concentration was found in mM by dividing Ts by 40 
l, the amount of sample supernatant added to the well. These values were divided by 0.8 
to correct for the fact that deproteinization dilutes the samples to 80% of their original 
concentrations. Finally, to account for variations in the mass of the tissue samples, the 
values were divided by the mass of the tissue sample from which it came to yield final 
values in mM/mg. Two independent samples from each group were measured in two 
independent trials, and the four values were averaged to produce a single data point per 
group.  
Caspase 
Following the storage protocol, hearts were frozen in OCT molds, transported in 
liquid nitrogen, and stored at -80 C. Each sample was then sectioned to 6 m thickness 
on a Cryostat (Microm HM550, Thermo Scientific), mounted on pre-cleaned Superfrost 
Plus slides (Fisher Scientific), and stored at -80 C. When ready for analysis, slides were 
warmed to -20 C in the freezer and labeled with pencil. The slides were fixed by 
immersion in -20 C acetone for 2 minutes at room temperature, and then rinsed in 0.2% 
Tween-20 in 1x PBS three times, 5 minutes each. This same rinsing procedure was used 
between each of the following blocking and incubation steps. After fixation, endogenous 




incubating in the humidifier box for 10 minutes at room temperature. The samples were 
then blocked with 5% normal goat serum (Jackson ImmunoResearch, West Grove, PA) in 
1x PBS for one hour at room temperature. After rinsing, endogenous biotin was blocked 
by first incubating in unconjugated streptavidin (Jackson ImmunoResearch, West Grove, 
PA), and then in free biotin (Sigma-Aldrich, St. Louis, MO) to saturate the binding sites 
on streptavidin, both at 10 g/mL in 1x PBS for 1 hour at room temperature with a 
rinsing step in between the two incubations. Slides were then incubated in purified rabbit 
anti-active caspase-3 primary antibody (BD Pharmingen, San Diego, CA) diluted 1:75 in 
Antibody Diluent, which was provided with an Anti-Ig HRP Detection Kit (BD 
Pharmingen, San Diego, CA), in the humidifier box for 1 hour at room temperature, then 
rinsed. The sample was then incubated in biotin-conjugated goat anti-rabbit secondary 
antibody (Jackson ImmunoResearch, West Grove, PA), 1:500 in Antibody Diluent, in the 
humidifier box for 30 minutes at room temperature. After rinsing, streptavidin-HRP from 
the Anti-Ig HRP Detection Kit was applied to the slides, which were then incubated in 
the humidifier box for 30 minutes at room temperature. Slides were rinsed, then 
incubated in DAB Substrate Solution (1 drop of DAB Chromogen per 1 mL of DAB 
Buffer) made from the DAB Substrate Kit (BD Pharmingen, San Diego, CA) for 5 
minutes at room temperature. The sample was then rinsed in water three times for 5 
minutes each. The slides were then counterstained by applying hematoxylin for 30 
seconds, rinsing thoroughly in water, dipping slides twice in Bluing Reagent, and rinsing 
again in water. The samples were dehydrated in four changes of ethanol of 95%, 95%, 
100%, and 100% for 5 minutes each at room temperature. They were then cleared in 




coverslip was applied to the slide with Cytoseal mounting solution (Fisher Scientific). 
Samples were visualized with an Axiovert 40CFL inverted light microscope (Zeiss; 
Thornwood, NY).  
Tissue F ixation and Slicing 
Frozen hearts were sectioned to 6 m thick sections, mounted on glass slides, and 
stored at -80 C as described for the caspase staining. When ready for analysis, slides 
were warmed to -20 C in the freezer and labeled with pencil. The slides were fixed by 
immersion in -20 C acetone two times for 10 minutes at room temperature, with at least 
10 minutes of air-drying after each acetone incubation. Slides were then incubated in 
95% ethanol for two minutes, followed by a wash in distilled water for two minutes. 
Then a 6.5 minute hematoxylin immersion was followed by a 2 minute rinse in tap water. 
Next, the slides were immersed in Clarifier 2 (Richard-Allan Scientific) for 45 seconds, 
followed by another 2 minute rinse in distilled water. Slides were then immersed in eosin 
for 15 seconds. The samples were then dehydrated in five changes of ethanol of 70%, 
95%, 95%, 100%, and 100%, in order for 3 minutes each. They were then cleared in a 3 
minutes incubation in Citrosolv (D-Limonene). A coverslip was applied with Cytoseal 
mounting solution (Fisher Scientific). Samples were visualized with an Axiovert 40CFL 
inverted light microscope (Zeiss; Thornwood, NY). 
All samples were stained at the same time in a single experiment in order to 
prevent procedural variability between stainings. Slides were stained and labeled with a 
code by one pair of experimenters, and a third experimenter performed a blind analysis of 
the samples using light microscopy. The code was not revealed until all data had been 





Controlled Release of H2S 
H2S decays over time 
The objective of the experiment performed in Figure IV-1A was to determine the 
change in H2S concentrations in a solution over time, as a first step in assessing the 
timeframe under which experiments utilizing H2S should be performed.  
It was hypothesized that H2S, being a volatile gas, would evaporate rapidly from 
solution, thus presenting difficulties in containing the gas for long enough to perform 
assays with it. In this experiment, a 25mM NaHS solution was prepared in distilled water, 
as described in the methods, and subsequently stored in a glass screw-cap container at 
room temperature. The absorbance from a sample of the nominal 25mM NaHS solution 
was monitored spectrophotometrically over a time frame of 3 to 26 days after making the 






F igure I V-1: Temporal change of H2S. (A) Decay of H2S concentration of a stock solution initially 
containing 25 mM NaHS in distilled water, over time. The 25mM NaHS stock solution was stored at room 
temperature in a glass, screw-top container, and the absorbance was monitored over 26 days. (B) Decay of 
H2
measurements. Error bars shown represent percent error of the triplicate measurements 
As seen in Figure IV-1A, spectrophotometric absorbances were converted to H2S 






H2S gas over the 24-day period, suggesting some dependence of the rate of decay on the 
concentration (higher concentration results in faster escape of H2S from solution). By the 
26th day, the concentration remaining is 0.5% of the initial concentration. Samples from 
each time point were collected and read in triplicates, and standard deviations were 
calculated for the readings. Due to unreasonably large standard deviation for the day-5 
time point, this data point was removed from the set. The standard deviations for the 
other data points are less than 10% of the measurement, except for the two lowest 
concentrations, where the standard deviation amounts to 33% and 50% of the 
measurements, respectively. These large errors may be due to the limit in sensitivity of 
the spectrophotometer at distinguishing very low concentrations. The resultant pattern of 
H2S decay allowed the team to determine an appropriate timeframe for which H2S 
remains in solution and can be effectively worked with in vitro. Effectively, the results of 
this experiment determined the timeframe under which future experiments using H2S 
could be performed. All subsequent experiments using H2S were performed within three 
days of making NaHS solution. 
The same experiment was performed to investigate the pattern of H2S decay at an 
H2S concentration and timeframe more relevant to our application. A 250 M NaHS 
solution was prepared and its concentration was tracked over a period of six hours, our 
target period for cold-storage of the heart. The literature reports therapeutic H2S 
concentrations from 1-33 M, which is yielded by 3-100 M NaHS solution. Due to 
previously observed limitations of the spectrophotometer in distinguishing very low H2S 
concentrations, the study investigated 250 M NaHS, a slightly more concentrated 




duplicate. Between time points, the solution was stored in a closed 1.5 mL 
microcentrifuge tube. The results (Figure IV-1B) show a similar pattern of decay to the 
previous study. Aside from an unusual rise in concentration between 0.5 and 5 minutes, 
the plot shows the concentration drops continuously. After six hours, the concentration of 
the original 250 M NaHS solution dropped to 60 M NaHS, roughly a quarter of the 
original concentration. The standard deviations were low, all less than 5% of the 
measurement. This experiment confirms that H2S depletion from solution occurs at 
concentrations and storage times that are protective in cold-stored hearts.  
Gelatin microspheres can be fabricated using an atomizer approach 
The objective of the experiment performed in Figure IV-2 and Figure IV-3 was to 
fabricate gelatin microspheres small enough to effectively be able to pass through blood 
vessels and capillaries. The team hypothesized that using a hybrid approach (where an 
atomizer is used to form the microspheres and a stirring oil solution is used to cure them) 
would yield smaller microsphere particles than previously described microsphere 
fabrication methods without the use of specialized equipment. Microspheres were 
fabricated from Type A gelatin derived from porcine skin, as described in the methods 
(See Section III). Results indicate that utilizing this hybrid method, yielded small 
microsphere particles, as depicted in Figure IV-2. A 50 µm scale bar is shown in the 
figure for comparison of fabricated microsphere sizes. Microsphere sizes appear to be 
much smaller than the 50 µm scale bar, and microsphere size was quantified using a 
Zeiss microscope and SPOT image analysis software. Figure IV-3 is a histogram that 
depicts the size distribution of microspheres fabricated by the atomizer method. The 




range of microsphere diameters (µm). This representative data were obtained from a 
single batch of microspheres, yielding an average diameter of 4.62 ± 1.54 µm, for n= 144 
microspheres counted in the batch. 
 






F igure I V-3: Histogram representation of microsphere size distribution. Average diameter = 4.62± 1.54 
µm, n=144 microspheres counted from a single fabricated batch. Our achievement of microsphere size less 
than 10 µm in diameter is of importance in preventing blockage of capillaries of the rat model heart. 
 
NaHS can be loaded into gelatin cylinders 
It is of importance to emphasize the difference between NaHS and H2S, as they 
are referred to in this experiment and in other experiments. NaHS is the colorless, solid 
reagent added to solution in our experiments. Upon dissolving, NaHS solid hydrolyzes 
into H2S gas, the product that is of interest to measure in experimentation. Hence, loading 
values and measurements refer to NaHS, as NaHS is the compound dissolved in solution 
and added to the assays conducted. However, H2S is the product of interest that is 
measured spectrophotometrically or by other means. Thus, values of release refer to the 
release of H2S, not NaHS. The purpose of the experiment performed in Figure IV-4 is to 




cylinders can retain H2S gas, in preparation for following experiments that entail the 
loading of NaHS and release of H2S by carefully fabricated gelatin microspheres. 
Controls for this experiment are the same loading solutions, but without gelatin discs. 
These controls provide a measure of how much H2S is lost to the atmosphere in the 
experimental group. Results of gelatin cylinder construct loading are shown in Figure IV-
4.  
 
F igure I V-4: Gelatin cylinders loaded with varying H2S concentrations. Bar graph displays concentration 
of NaHS loaded to gelatin cylinder constructs versus H2S concentration (mM) absorbed by microspheres, 
for loading concentrations of 25, 50, and 100 mM NaHS. Uptake of H2S was calculated as the difference in 
the amount of H2S  ((C2  C1)*volume) between two time points, subtracting the amount lost to the 
atmosphere. Standard error is shown for duplicate measurements. 
 
The concentration of H2S absorbed or taken up by gelatin cylinders is plotted 
against the loading of 3 different initial concentrations of NaHS solutions (25, 50, and 




calculated from measurements of the concentration in the bulk solution. Concentrations 
of H2S were measured spectrophotometrically. H2S uptake was calculated by the 
following formula: 
H2S uptake  = (Amt H2S in bulk solution at t = 5 min, after sampling) - (Amt H2S 
in bulk solution at t = 60 min) - (Amt H2S lost to atmosphere) 
 = ((C5,e - C60,e)*(200 µL) - (C5,e)*(10 µL)) - (C5,c- C60,c)*(200 µL) 
where Ct,e or Ct,e represents the concentration at time t (min), for experimental or control, 
respectively.  
The experiment was performed in duplicate (two discs loaded per loading 
concentration), and the standard error is shown for the two trials. T-tests indicate the 
percent decrease in bulk concentration is significantly higher for each experimental group 
compared to its corresponding control, indicating that the gelatin discs lowered the 
concentration of the bulk solution by absorbing H2S. The plot also indicates that with 
increasing initial loading concentration of NaHS solution, the concentration of H2S taken 
up by gelatin cylinders also increased. In other words, in a moderately linear fashion, 
increasing loading NaHS concentration corresponded to increased uptake of H2S by 
gelatin cylinders. The rough linearity in H2S absorption by gelatin cylinders indicates the 
capacity of gelatin material to retain H2S, thus making gelatin a useful compound for 
microsphere production. Importantly, an almost 3-fold increase was seen in H2S uptake 
between 25mM and 100mM initial loading concentrations of NaHS solution. Moreover, 




and 50 mM loading concentrations, and between 50 and 100 mM loading concentrations  
(p-value = 0.03% and 1.5%, respectively).  
H2S release from microspheres 
The objective of this experiment was to determine whether factors in microsphere 
fabrication such as glutaraldehyde concentration used for crosslinkage of gelatin, and 
time allowed for release, affected release profiles of H2S from microspheres. 
Microspheres were fabricated and crosslinked as described in methods, with crosslinking 
concentrations of 1M glutaraldehyde and 4.75M glutaraldehyde. In the experiments 
described in Figure IV-5 and B, the net release of H2S (mmoles) per mg of microsphere 
was monitored over a 360 minute, or 6-hour period. The experiment was done for 
microspheres loaded with initial loading concentrations of 25, 50, and 100mM NaHS in 
micro-centrifuge tubes. The loading solution was removed and fresh 1X PBS was added 
to the tube at t=0. At each time point collected in the experiment, 50 µL of the bulk 
solution from the tubes containing microspheres were removed and replaced with the 
same volume in 1X PBS. The absorbance of the 50 µL sample was measured 
spectrophotometrically for time points of 0.5, 60, 120, 180, 240, 300, and 360 minutes. 
The net release of H2S was calculated for each time point collected, and represented the 
cumulative release of H2S at that particular time point. The net release was then divided 
by the corresponding mass of the microspheres, so that the end measurement is amount of 





















F igure I V-5: Release of H2S from crosslinked gelatin microspheres. Net H2S (mmoles) released per mg of 
microspheres over time (minutes). Data shown represents microspheres crosslinked with 4.75 M and 1 M 
glutaraldehyde loaded with 25 mM NaHS solution. The amount of H2S released has been normalized by 
mass. Data demonstrates that the lower crosslinking microspheres releases more H2S, possibly because the 
molecule is able to diffuse from lower crosslink networks more easily. 
 
The results can be divided into 3 categories, based on the variable of interest: 
effect of crosslinking density of microspheres, effect of loading concentration, and effect 
of microspheres. 
E ffect of crosslinking density of microspheres 
The net release of H2S over time was compared for 1 M and 4.75 M GA 
concentrations (Figure IV-5), fixing the loading concentration at 25 mM NaHS. The plot 
shows that 1M GA crosslinked microspheres released more H2S than 4.75 M GA 
crosslinked microspheres. The range of cumulative release from 1 M GA crosslinked 






cumulative release range from 1.4 to 1.8 nmoles. The consistency of these differences 
between the 1 M GA and 4.75 M GA release profiles suggests the trend towards larger 
amount of release from 1 M GA cross-linked microspheres is significant. However, there 
is wide variability amongst the three identical groups at each time point for both 1 M GA 
and 4.75 M GA, as seen by the large standard deviations at each time point (ranging from 
80% to 94% of the measurements for the 1 M GA set, and 27% to 92% of the 
measurements for the 4.75 M GA set). An ANOVA comparison test of the net amount 
H2S released/mg microspheres between the 1 M and 4.75 M GA-cross-linking 
concentrations was performed at each time-point. Differences in H2S release between 1 
M and 4.75 M GA-crosslinked microspheres approach significance from the beginning 
time-points, and are below 10% for all time-points tested . However, only the 300 minute 
time-point had a p-value below 5%, to strongly support the significance of this trend (see 
Table IV-1 in appendix). 
For microspheres crosslinked with 1M glutaraldehyde, results indicate a continual 
decrease of net H2S release per mg of microspheres after 120 minutes, as shown in Figure 
IV-5. The cumulative amount of H2S released by these microspheres drops by 17% of the 
amount released at 120 minutes, indicating the rate of H2S lost from the system 
overwhelms the rate of H2S release from the microspheres in the latter portion of the 
release profile. In general, the changes in H2S concentration, shown in Figure IV-7, 
mirror the cumulative release profile. By the 360 minute data point, the concentration has 
dropped to 70% of its original concentration. In contrast, for microspheres crosslinked 
with 4.75 M glutaraldehyde, results do not show the same negative trend shown by 1 M 




between time points of 0 and 60 minutes, with relatively marginal, variable increases and 
decreases afterwards. By the 360 minute data point, the concentration actually is higher 
(114%) than the original concentration.  
E ffect of loading concentration 
The net release of H2S over time was compared for loading concentrations of 25 
mM, 50 mM, and 100 mM (Figure IV-6), fixing the crosslinking density at 4.75 M GA. 
The plot shows clearly that with higher loading concentration, more H2S is released. The 
cumulative release has a range of 1.4-1.8 nmoles for 25 mM loading, 2.7-4.0 nmoles for 
50 mM loading, and 4.4-7.7 nmoles for 100 mM loading. These large differences 
contribute to the significance of the trend, despite wide variability in the data The 
weakest significance comparison was  for 25 mM and 50 mM loading concentration, 
where p values were significant only at the last two time points (t = 300 and t= 360 
minutes), for which the standard deviation is relatively small. The differences in release 
between the 50 mM and 100 mM load NaHS concentrations are all significant after t = 30 
minutes. Comparison of microspheres loaded with 25mM and 100mM NaHS shows the 
most striking significance in the difference in net release of H2S. The significance in 
differences between release profiles of H2S for the 25mM and 100mM NaHS loaded 
microspheres is noticed at the first time-point (p= 0.029). The significance in the 
difference becomes more striking at later time ( p = 0.0018 at 120 minutes, p = 0.0007 at 
180 minutes, p = 0.00034 at 300 minutes, and p = 0.0011 at 360 minutes). 
For both 50 mM and 100 mM loading concentration, the release profile has a 
characteristic increase up to 120 minutes (67% and 50% of the t=0.5 min value, 




the concentration at the last time point measured still represents an overall increase 
(104% and 132%, respectively) over the initial concentration (though this increase does 
not reach significance for either group). 
 
F igure I V-6: Net H2S (mmoles) released per mg of microspheres over time (minutes). Data shown 
represents net H2S released from microspheres crosslinked with 4.75M glutaraldehyde, and loaded with 25 
mM, 50 mM, and 100 mM NaHS solution. The amount of H2S released has been normalized by mass. Data 
demonstrates that we can control H2S release by changing loading concentration of NaHS. 
 
E ffect of microspheres vs. control (no microspheres) 
The overall trends presented above are best understood in the context of Figure 
IV-7. The concentrations at each time point were normalized by the initial concentration, 
so that each value plotted represents the fraction of the starting concentration that remains 
at that time point. The plot shows the concentrations of the bulk solutions for different 
experimental groups compared with a control set, which was only a solution of NaHS at a 
particular concentration without microspheres. As expected, the concentrations in the 




25 mM NaHS loaded, 1 M GA crosslinked microspheres, the concentration fraction is 
significantly higher compared to the control between t=60 and t=180 minutes (p = 0.0414 
at t = 60 min, p=0.0321 at t=180 min), but not thereafter. In contrast, for the 25 mM 
NaHS loaded, 4.75 M GA crosslinked microspheres, the concentration fraction appears 
higher than control, but only at an early time-point is this difference significant (p = 
0.0337 at t = 15 min). Overall, the difference between experimental and control scenarios 
is most significant for 100 mM loaded, 4.75 M GA crosslinked microspheres. In this set, 
the concentration fraction is significantly higher than control (p<0.05) at all time points, 
with the exception of t = 15 min and t = 300 min (p = 0.2297 and p = 0.0608, 
respectively). 
 
F igure I V-7: Change in bulk solution concentration over time for experimental and control (no 
microspheres) groups. Bulk concentration (as fraction of bulk concentration at t= 0.5 min) over time 
(minutes). The concentration in the control group continuously falls. 4.75 M GA, 100 mM loaded 
microspheres keep the bulk solution from decreasing in concentration, presumably by releasing H2S. The 
other two experimental groups are not as effective throughout the timeframe. Data demonstrates the 






The results presented in Figure IV-5 to Figure IV-7 indicate that the crosslinking 
concentration of GA and the loading concentration of microspheres have an impact on 
the release-profile of H2S over time. Namely, as our results indicate above: a higher 
crosslinkage (4.75M GA)  yields less release of H2S, higher loading concentrations 
(100mM NaHS) yield more release of H2S, and microspheres with high crosslinkage and 
high loading concentration yield significantly more stable release profiles than groups 
without microspheres.  
Controlled Release of H2S in vitro 
H2S-loaded microspheres do not induce significant apoptosis 
The objective of this experiment was to investigate the effect of introducing blank 
microspheres and microspheres loaded with NaHS on cell survival, in order to determine 
the concentration of H2S that is safe for use on the heart organ in the rat model system 
used. Microspheres were fabricated and crosslinked with 1M glutaraldehyde. Sets of 50 
mg, 100 mg, and 250 mg microsphere masses were weighed and loaded with 100 mM 
H2S overnight. H9c2 murine cardiomyocytes were seeded at 1.0 X 104 cells/cm2 on 6 
well plates and grown to 90% confluence. 0 mg, 50 mg, 100 mg, and 250 mg of loaded 
and blank/non-loaded microspheres were added to the cells and incubated for 1 hour. 
After 1 hour incubation, cells were stained with ethidium homodimer and calcein AM 
and live-dead cell counts were performed through microscopy and imaging. Live-dead 
images are shown in Figure IV-8 where Row A depicts non-loaded control microspheres 
and Row B depicts loaded experimental microspheres. Masses are 0 mg, 50 mg, 100 mg, 
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F igure I V-8: Viability assay results for cardiomyocytes incubated with varying [H2S]. All cells were 
approximately 90% confluent at the time of the assay. Cells were seeded 2 days prior to conducting the 
assay. 
Row (A): Representative control samples, microspheres incubated in absence H2S. Images depict 
cardiomyocytes incubated with 0, 50, 100, and 250 mg of microspheres (from left to right). 
Row (B): Representative experimental samples, microspheres incubated in presence of 100mM H2S. 
Images depict cardiomyocytes incubated with 0, 50, 100, and 250 mg microspheres (from left to right). 
Assay was conducted upon 1 hour incubation of cells with H2S.  
 
Live-dead cell counts were performed in triplicate and cell survival is shown as a 
percentage of live cells per total number of cells in the assayed well. For 0 mg of 
microspheres, the experimental group, which consists of microspheres loaded with 
NaHS, displayed significantly higher levels of cell survival than the 100 mg microspheres 
of the experimental group (p<0.001). The control and experimental groups show 
comparable levels of cell death to the 50 mg microsphere sample, but the experimental 
group has lower death than the control group. The 100 mg experimental group has 
significantly more cell death than each of the other experimental groups and only 85% of 
the cells retain viability. The 50 and 250mg experimental groups show comparable levels 
of apoptosis to the 0mg experimental group (p>0.05). However, the experimental group 




mg experimental group has lower cell death compared to the 250 mg control group, but 
the 250 mg control group has a large standard deviation. The control group displayed 
increased cell death as the amount of microspheres added increased. The 0 and 50mg 
control groups did not display significantly different amounts of cell death; however the 
remainder of the groups differed from the 0mg control (p<.002). Differences were 







F igure I V-9: Quantitative representation of cell death for control cell samples. Each bar depicts the 




Rat cardiomyocytes display similar metabolic activity 
The objective of this experiment was to investigate the effect of NaHS on 
cytotoxicity and ensure that there are no detrimental effects of NaHS. H9c2 murine 
cardiomyocytes were seeded at 1.0 X 104 cells/cm2 on 6 well plates and grown to 90% 
were added to the cells and incubated for 3 hours. After incubation the MTT assay was 
performed as specified in the methods and the results are depicted as relative change in 
spectrophotometrically-measured absorbance.  
Three biological replicates and three technical replicates were performed and 
standard deviations are shown (Figure II-1). It can be seen that there is no significant 
change in relative metabolic activity between the control group and the 10 and 1,000 µL 
groups. Decreased metabolic activity was observed in the 10,000 µL group (p<.005). The 
trend was a slight decrease in metabolic activity as the concentration of NaHS increased 





F igure I V-10:.Effect of H2S on cardiomyocyte viability. Relative metabolic activity, measured 
by means of MTT assay, for cardiomyocytes incubated with 0, 10, 1,000, and 10,000 µL volumes 
of 100mM NaHS for 3 hours. Data for each bar depicts the average of three biological replicates, 
with standard deviations shown. ANOVA revealed a significant difference between groups (with 
a p value of 1.37E- -tailed multiple comparison test revealed that there was no 
significant difference in the percent of live cells between the 0mg control and the 50mg group, 
but the remainder of the groups varied from each other. Groups marked with a * do not vary 
statistically. 
 
H2S temporal release from microspheres with murine cardiomyocytes 
varies with mass 
The temporal release profile of H2S into cell media using H2S-loaded 
microspheres in the presence of murine cardiomyocytes was investigated. Microspheres 
were fabricated and crosslinked with 4.75M glutaraldehyde as previously mentioned. 
Varying microsphere masses of 50 mg, 100 mg, and 250 mg were weighed and loaded 
with 100 mM H2S overnight. The microspheres were added to cell media and H2S 
concentration in media was measured at 0, 15, 30, and 60 minutes. Results are shown as a 




percentage decrease from the initial H2S concentration in the media, in order to account 
for differences in initial H2S concentration between the control and experimental groups. 
The control experiment in Figure IV-11 demonstrates the release profile of H2S-loaded 
microspheres in media without the presence of murine cardiomyocytes. The experiment 
in Figure IV-12 investigates the effect of cells on the release profile of H2S-loaded 
microspheres. H9c2 murine cardiomyocytes were seeded at 1.0 X 104 cells/cm2 on 6-well 
plates and grown to 90% confluence prior to microsphere addition. Six biological 
replicates were performed and averages with standard deviations are shown.  
 
F igure I V-11: Cellular release profiles of H2S. Net [H2S] released in cell media only over time with 







F igure I V-12: Net [H2S] released over time microspheres loaded with NaHS in cell media with 
cardiomyocytes. Microspheres were crosslinked with 4.75M GA. 
 
Without cardiomyocytes in culture, as the mass of microspheres increased in 
solution, the percent decrease from the initial H2S concentration also increased in a time-
dependent manner. The addition of 50 mg microspheres into media resulted in the 
greatest percent decrease from initial H2S concentration for all time points with percent 
decreases of 32.7%, 46.3%, and 70.1% at 15, 30, and 60 min, respectively (Figure IV-
11).The 250 mg microsphere group had the smallest percent change for all three time 
points, with percent changes of 11.3%, 17.6%, and 42.3% for 15, 30, and 60 min, 
respectively (Figure IV-11).In between, 100 mg microspheres had percent decreases of 
19.0%, 30.7%, and 61.3% for 15, 30, and 60 min, respectively (Figure IV-11). 
To determine the effect of the mass of the microspheres on release of H2S into 
solution without cells, a statistical analysis was performed. Each of the three different 




decreases from initial H2S concentration over time between 50 mg and 100 mg were 
statistically significant (p<0.05), with the percent change in 50 mg microspheres 
statistically greater than that in 100 mg microspheres. Similarly, when comparing 100 mg 
and 250 mg microspheres, the percent decreases from initial H2S concentration were 
statistically different across all time points (p<0.05). The two groups with the greatest 
difference in mass, 50 mg and 250 mg microspheres, yielded statistically significant 
differences (p<0.001). As the difference in mass of microspheres increased, so did the 
difference in percent changes in H2S concentration, as shown by the decrease in p-values 
at the respective time point.  
H2S-loaded microspheres when added to cell media with cardiomyocytes 
exhibited the same trend of increasing percent decrease from the initial H2S concentration 
over time, or decreasing H2S concentration in media over time (Figure IV-12). As in the 
control, 50 mg of microspheres had the greatest percent change for all three time points 
with percent decreases of 52.4%, 59.1%, and 77.4% for 15, 30, and 60 min, respectively 
(Figure IV-12).250 mg again had the smallest percent decrease for all three time points 
with percent decreases of 29.2%, 42.8%, and 65.6% for 15, 30, and 60 min, respectively 
(Figure IV-12).In between, 100 mg had percent changes of 45.8%, 59.9%, and 76.6% for 
15, 30, and 60 min, respectively (Figure IV-12).  
A statistical analysis was performed comparing the percent decreases from the 
initial H2S concentration between different masses of microspheres. Although there was 
not a statistically significant difference between 50 mg and 100 mg of microspheres, 




microspheres at 30 min (p<0.05). The greatest disparity in mass, 50 mg and 250 mg of 
microspheres, yielded statistically significant differences in percent decreases from initial  
The presence of cardiomyocytes in cell media resulted in greater percent 
decreases from initial H2S concentration at all time points and at all three masses of 
microspheres tested, compared to the control without cardiomyocytes. With the delivery 
of H2S to cardiomyocytes, the decrease in H2S concentration in media was noticeably 
greater than in the control. 50 mg of H2S-loaded microspheres delivered to 
cardiomyocytes resulted in higher percent decreases from initial H2S concentrations at all 
time points (p<0.05). 100 mg of microspheres into cardiomyocyte culture compared to 
just media also had statistically significant differences in percent decreases from initial 
H2S concentration at 30 min and 60 min (p<0.01). Statistically significant differences for 
250 mg of microspheres were found at 30 min (p<0.05) and 60 min (p<0.001). 
Controlled release of H2S in vivo 
ATP content of stored hearts over time 
The objective of this experiment was to measure ATP content in tissue samples 
taken from the left ventricle of hearts that were stored in control and experimental 
conditions. The three control groups were C-frozen, C-ischemia+UW, and C-UW. The 
three experimental groups were E-UW+NaHS, E-UW+ S, and E-UW+ S+H2S. All 
hearts were stored in solutions for 8 hours and sampled every 2 hours, with the exception 
of the C-frozen group. Tissue samples were frozen and stored at -80 C after surgery, and 
were subsequently thawed and assayed as described in the methods section. The C-frozen 




ischemia+UW hearts were subjected to warm ischemia to stimulate apoptosis, and C-UW 
hearts were preserved in UW solution, as is the current clinical standard. Hearts in the E-
UW+NaHS group were stored in UW solution containing 25 M H2S. The E-UW+ S 
25 M H2S in solution and injected with PBS-loaded microspheres. The E-UW+ S+H2S 
group was stored in UW solution with 25 M H2S and injected with H2S-loaded  
microspheres. 
 F igure I V-13: ATP retained in whole rat hearts over time plotted by group. Error bars represent 
+1 standard error of the mean. C-frozen represents sample taken immediately after stopping the 
heart. C-ischemia+ UW represents hearts that underwent warm ischemia, stimulating apoptosis. 
C-UW represents the clinical standard, static storage with UW solution. E-UW+NaHS represents 
hearts stored with a modified UW solution which contained 25µM H2S. E-UW+ S represents 
hearts perfused with gelatin microspheres loaded with PBS, then stored in UW solutions with 
25 M H2S. E-UW+ S+ H2S represents hearts stored in modified UW solution with 25 M H2S 






Two independent biological samples were assayed in technical duplicate for every 
group. Thus each data point in F igure I V-13 and Figure IV-14 is the average of four 
distinct readings and is shown with its respective standard error of the mean. Constraints 
in time and funding limited the sample size to 2; larger sample size may find trends not 
observable using the smaller sample size, or may reinforce the significance in these 
differences. The ATP content is reported as mM/mg in order to control for varying tissue 
mass between samples. Tissue samples of hearts in the three control groups were taken at 
0, 2, 4, 6, and 8 hours, while tissue samples of hearts in the three experimental groups 
were taken at 2, 4, 6, and 8 hours. Although tissue samples from the 6-hour time point 
were not assayed for ATP content due to constraints in resources, the data indicates that 
there is no significant difference between ATP content at 4 hours and 8 hours in any of 
the groups. 
Data in each group was analyzed using ANOVA across time points to find 
significant decreases in ATP content over time (F igure I V-13). All groups demonstrated 
at least one significant difference in ATP content between time points (p < 
multiple comparison test was then used to find that in the C-ischemia+UW group, only 
the ATP content at 2 hours was found to be significantly greater than the ATP content at 
8 hours (p < 0.05). In the C-UW group, the ATP content at 0 hours was found to be 
significantly greater than that at 2 hours, 4 hours, and 8 hours (p < 0.05). No other 
significant differences were found in the C-UW group. In all three experimental groups, 
E-UW+NaHS, E-UW+ S, E-UW+ S+H2 content at 
2 hours was significantly greater than that at both 4 and 8 hours, but there were no 




< 0.05). The C-frozen group was not analyzed across time points because hearts in the C-
frozen group were frozen immediately following explantation and therefore were only 
sampled at the 0 hour time point, before hearts were frozen.  
F igure I V-14: ATP retained in whole rat hearts across groups plotted by time. Error bars 
represent ±1 standard error or the mean. C-frozen represents sample taken immediately after 
stopping the heart. C-ischemia+ UW represents hearts that underwent warm ischemia, stimulating 
apoptosis. C-UW represents the clinical standard, static storage with UW solution. E-UW+NaHS 
represents hearts stored with a modified UW solution which contained 25µM H2S. E-UW+ S 
represents hearts perfused with gelatin microspheres loaded with PBS, then stored in UW 
solutions with 25 M H2S. E-UW+ S+ H2S represents hearts stored in modified UW solution with 
25 M H2S and perfused with gelatin microspheres that were loaded with H2S overnight.  
 
Data across time points was also analyzed in each group using ANOVA, which 
showed that significant differences existed between groups at 0 hours (p< .0001) and 2 
hours (p< .001) (Figure IV-14). To determine which specific pairs of means were 
hours and 2 hours. Results showed that at 0 hours, the average ATP content of C-UW 
hearts was significantly greater than that of both C-frozen and C-ischemia+UW hearts (df 




st showed that both E-UW+ S and E-
UW+NaHS hearts had a significantly greater ATP content than C-ischemia+UW and C-
UW hearts (df = 15,  = 0.05, q = 4.37), but there were no significant differences in ATP 
content between C-ischemia+UW and C-UW groups, or between E-UW+NaHS, E-
UW+ S, and E-UW+ S+H2S groups. One-way ANOVA tests showed that there were no 
significant differences in ATP content at 4 hours (p = 0.22) or at 8 hours (p = 0.66) of 
storage. 
Apoptosis levels from caspase-3 staining 
The objective of this experiment was to qualitatively determine the amount of 
apoptosis in the tissue samples taken from the same rat heart experimental groups as 
those in the ATP protocols. Representative pictures from the caspase-3 assay are shown 
in Figure IV-15. As can be seen, the C-UW and E-UW+ S+H2S groups show deeper 
staining than that of the other groups. Also, the tissue of the C-frozen, C-ischemia+UW, 
E-UW+ S, and E-UW+ S+H2S groups show more tears and discontinuities while those 
of the C-UW and E-UW+NaHS groups are relatively intact, suggesting that the C-UW 
and E-UW+NaHS groups are better at protecting the morphology of the heart tissue. 
Although there is little discernable difference in the amount of tissue stained by the 






F igure I V-15: Representative sections of immunochemistry staining for tissue caspase 3. Frozen sections 
from heart tissue incubated with various experimental treatments for 4 hours were stained for activated 
caspase 3. C-frozen represents sample taken immediately after stopping the heart. C-ischemia+ UW 
represents hearts that underwent warm ischemia, stimulating apoptosis. C-UW represents the clinical 
standard, static storage with UW solution. E-UW+ NaHS represents hearts stored with a modified UW 
solution which contained 25µM H2S. E-UW+ S represents hearts perfused with gelatin microspheres 
loaded with PBS, then stored in UW solutions with 25 M H2S. E-UW+ S+ H2S represents hearts stored in 
modified UW solution with 25 M H2S and perfused with gelatin microspheres that were loaded with H2S 
overnight. Images were taken with a 40x objective lens. Scale bars represent 100 m.  
 
Tissue morphology from H &E staining 
The objective of this experiment was to analyze tissue samples for markers of 
gross tissue damage, including general morphology and infiltration with inflammatory 
cells. Representative images of hematoxylin and eosin (H&E) staining of tissue samples 
are shown in Figure #. One sample from each control (C-frozen, C-ischemia+UW, and C-






F igure I V-16: Representative sections of tissue morphology. Frozen sections from heart tissue incubated 
with various experimental treatments for 4 hours were stained with hematoxylin and eosin. C-frozen 
represents sample taken immediately after stopping the heart. C-ischemia+ UW represents hearts that 
underwent warm ischemia, stimulating apoptosis. C-UW represents the clinical standard, static storage with 
UW solution. E-UW+ NaHS represents hearts stored with a modified UW solution which contained 25µM 
H2S. E-UW+ S represents hearts perfused with gelatin microspheres loaded with PBS, then stored in UW 
solutions with 25 M H2S. E-UW+ S+ H2S represents hearts stored in modified UW solution with 25 M 
H2S and perfused with gelatin microspheres that were loaded with H2S overnight. Images were taken with a 





Controlled release of H2S 
Fabricating microspheres 
The ability to fabricate hydrogel microspheres under the size of 10 µm is crucial 
in the future application to human models as any larger would cause infarctions. We have 
been able to consistently create hydrogel microspheres well below the limit, 
averaging 4.62±1.54 microns. Although outliers greater than ten microns occasionally 
appear, the application of a vacuum filter removes any microspheres >10µm. Equally 
important is the ability for the microspheres to release H2S at a constant rate and in 
controlled amounts. 
It is important to note that while this study provided a successful manner to 
produce these microspheres within the 10 µm limit, the procedures executed in previous 
studies produced microspheres of more than 50 µm, approximately five times the size of 
 
alterations to optimize the procedure to the needs of the current experiments were added. 
In particular, the porcine gel was distributed evenly using an atomizer, which was 
continually washed in between experiments to prevent aggregation of the porcine gel 
microspheres. Aggregation could lead to an increased microsphere radius and clumping 
of the microspheres. As a result, it is advised that between experiments, the atomizer be 
heated and rinsed to remove any excess porcine gel. In an effort to ensure the accuracy of 





H2S depletes from solution 
Figure IV-1 shows the dramatic drop in H2S concentration from a closed solution 
over time, for both a large (days) and small (hours) time window, as a result of the H2S 
escaping the solution as a volatile gas. The experiment was performed by taking a sample 
from the solution at the stated time-point and measuring H2S concentration. Two 
concentrations (25 mM and 250 M) were tested to show that H2S loss can also be 
observed at therapeutically relevant concentrations.  
Between time-points, the solution was closed in a 1 L glass screw-top container, 
or in a 1.5 mL plastic micro-centrifuge tube (Figure IV-1). The likely contributing 
process to the drop in H2S levels over time is H2S volatility. A certain concentration (or 
pressure) of H2S exists at the air-solution interface, which is proportional to the solution's 
H2S concentration, according to Henry's Law. At 25o C, the Henry's Law constant for 
H2S is 9.8 atm/M, or, for every mole of H2S per liter of solution, there exists around 0.4 
moles of H2S per liter air. With higher concentrations, more H2S would exist in the head-
space above the solution; the steeper rates of loss at higher concentrations in Figure IV-1 
support this concentration dependence. Moreover, the amount of H2S in the head-space 
above the solution is related to the volume of the head-space. Thus, the head-space 
volume was controlled by ensuring the solution (1.5 mL) filled the 1.5 mL micro-
centrifuge tubes to the brim.  
However, due to imperfect seals in the containers, H2S in the head-space can 
continuously leak out of the system, despite the containers being closed. In addition, the 
solution is repeatedly opened and closed at each sample point, which also contributes to 




being opened at the sampling times, we compared two situations. In one case,  the 
concentration of a 250 M NaHS solution in a 1.5 mL micro-centrifuge tube was 
sampled at t = 5 and t= 360 minutes only, and closed in the in-between interval. In the 
other case, 250 M NaHS solution was sampled at t= 5, 15, 30, 60, 120, 180, 240, 300, 
and 360 minutes, and otherwise remained closed. Despite the solution being closed after 
the initial sampling in the first case, the concentration decreased to 63% of its initial 
value by the 6 hour time-point (data not shown). This decrease over 6 hours is 
significantly larger than the concentration decrease between two time-points spaced just 
15 minutes apart (10%). Importantly, this result suggests that H2S is being lost even when 
the container is closed. As expected, the concentration decrease at the 6-hour time point 
(24% of initial value) was significantly larger for the tube that is opened repeatedly to 
obtain samples. Thus, the continuous loss of H2S during the period that the tube is closed 
is roughly half of the total, observed loss when taking samples throughout the six-hour 
period. At lower temperatures, it is expected that the depletion of H2S due to volatility 
will also be lower, due to the inverse dependence of the Henry's Law constant on 
temperature. However, H2S will continue to be depleted through other processes, 
including catalyzed oxidation of sulfide and biologically mediated metabolism (see 
Section 0 of this chapter, a discussion on cardiomyocyte H2S consumption). Thus, if a 
stable H2S concentration is desired for therapeutic applications, simply using a closed 
solution of NaHS is not an effective option.  
Our observations of H2S depletion from closed containers is consistent with 
observations made by other researchers. Typically, experimenters using H2S from NaHS 




or create a stock solution that is used within 3 days (Dombkowski et al., 2003). Following 
this standard, our experiments involving NaHS solution were done within three days of 
preparing the stock solution. 
H2S can be sorbed to gelatin discs 
Figure IV-4 shows the capacity of 1 M glutaraldehyde crosslinked gelatin discs to 
uptake hydrogen sulfide. Dried gelatin discs were loaded with varying concentrations of 
NaHS. There is a clear trend towards higher uptake of sulfide with higher loading 
concentration. The mechanism by which H2S is associated with the gelatin may be 
physical or chemical. Tabata et al. describes an application of gelatin microspheres that 
incorporates basic fibroblast growth factor (bFGF). They tested release profiles of bFGF 
from microspheres composed of basic or acidic gelatin, which have isoelectric points of 9 
and 5, respectively. During loading, solution with bFGF was added to dried gelatin 
microspheres. The swelling of the microspheres in solution allowed bFGF to enter. The 
negative charge of bFGF formed polyionic interactions with the acidic type of gelatin, 
and so the release of bFGF was observed to be prolonged and dependent on the 
degradation of the gelatin carrier. In contrast, bFGF in basic gelatin microspheres had no 
other forms of association and simply diffused out at a much faster rate of desorption. 
NaHS dissociates into SH-, in equilibrium with H2S (and small amounts of S2-). 
The gelatin used in our studies was porcine gelatin (G2500, Sigma Aldrich) which, due to 
the acidic pretreatment, likely has an isoelectric point that would allow it to interact with 
the SH- anion. It is possible that both ionic interactions and physical constraints, provided 




Future work may target what effect ionic interactions have on the release of H2S from 
microspheres. 
Increased crosslinking density slows initial release of H2S  
Figure IV-5 shows the release profiles of H2S from microspheres fabricated at two 
different crosslinking densities, 1 M and 4.75 M glutaraldehyde (GA). The 1 M GA 
microspheres, on average, released more than three times the amount of H2S per 
milligram than 4.75 M GA microspheres, starting from the first measured time-point. As 
the ANOVA comparisons show, this difference did not reach the significance level, but 
approached it. The wide variability, particularly in the 4.75 M GA data, contributed to the 
high p-values. It is likely that repeated trials will strengthen this trend and move the p-
value below 5%.  In both groups, the first bout of release from 0 to 0.5 minutes is by far 
the largest amount released between two time-points. This burst release is set up by the 
large concentration gradient between the inside and outside of the microspheres in the 
beginning of the experiment, when there is no H2S in the bulk solution. There is 
relatively little change measured in net amount released per milligram thereafter. 
However, in the case of 1 M GA microspheres, the rate of decrease is more pronounced; 
by the end of the experiment, they had lost 12% of the amount released at the first time 
point. In contrast, the 4.75 M GA microspheres had a release profile characterized by 
periods of loss and periods of release throughout the time window. The net result by the 
end of the experiment was only a 4% loss from the amount released at the first time point.  
As the ANOVA test did not yield significant results, this comparison, too, needs more 




release of H2S compared to 4.75 M GA microspheres, but stopped releasing H2S before 
the end of the time-window. 4.75 M GA microspheres had a smaller burst release, and 
preserved enough H2S in the microspheres to continue releasing H2S to the bulk solution 
throughout the time-window. This result may not be readily apparent from the plots, 
which do not reflect an actual increase in net amount of H2S released for 4.75 M GA 
microspheres. However, it is important to note that net amount of H2S released 
underestimates the actual amount of H2S released from the microspheres. The net amount 
of H2S released between two time points is calculated by the difference between the 
concentration after sampling at the time point and the concentration at the next time point 
(see methods). If these two concentrations are the same, the net amount of H2S released is 
calculated to be zero. However, this only indicates the rate of H2S release by 
microspheres is exactly balanced by the rate of H2S loss to the atmosphere. Thus, if the 
amount of H2S lost to the atmosphere were reliably incorporated into the calculations, the 
plot of total H2S released would show a steadily increasing trend-line for the 4.75 M GA 
microspheres.  
Because of the normalization by mass, the observed difference between the burst 
release from the two types of microspheres must be attributed to characteristics of the 
microspheres themselves. The crosslinking density of the microspheres is expected to be 
proportional to the GA concentration used in their fabrication. A higher crosslinking 
density would reasonably lower the amount of H2S that can diffuse out of the 
microspheres, through a caging-type effect that traps the H2S inside the microspheres. 




from gelatin microspheres and the crosslinking density of the microspheres in similar in 
vitro release experiments. Moreover, it is likely the initial burst release from 1 M GA 
microspheres depleted the H2S in the microspheres, so the net amount released decreases 
thereafter.  
Higher concentration of loading solution results in higher net H2S 
released 
Figure IV-6 shows the direct relationship between the concentration of the 
loading solution and the net amount of H2S released per milligram of microspheres, 
fixing the crosslinking density at 4.75 M GA. Microspheres loaded in 100 mM and 50 
mM NaHS solution released more than 4 and 2 times the amount of H2S per milligram 
than microspheres loaded in 25 mM NaHS solution. This dependence on the loading 
solution concentration is reasonable because diffusion of H2S into microspheres is related 
to the concentration gradient set up between the loading solution and inside of the 
microspheres. Thus, more H2S is loaded into microspheres with higher loading 
concentration. When the loading solution is replaced by fresh PBS at the start of the 
experiment, the concentration gradient between the inside and outside of the 
microspheres this time motivates diffusion of H2S out of the microspheres.  
Moreover, with more H2S loaded in microspheres, the microspheres release more 
H2S throughout the time window, not only during the first few minutes. By the end of the 
experiment, the 4.75 M GA crosslinked, 100 mM NaHS loaded microspheres had 
released 70% more than the initial amount released in the first 0.5 minutes and the 50 




4.75 M GA, 100 mM NaHS loaded gelatin microspheres preserve H2S 
concentration  
The above trends are corroborated by data comparing the actual concentrations of 
the solution in the tube, with or without microspheres. The end goal of creating H2S-
loaded microspheres is to continuously release H2S to the bulk solution, such that the 
concentration of the bulk solution does not drop. Our control group thus was a NaHS 
solution without microspheres, with a starting concentration comparable to the 
concentration measured in the first time-point of the experimental groups with 
microspheres (150  640 M H2S). As expected, the concentration of H2S drops in the 
control throughout the experiment, due to two contributions: sampling (replacing 50 µL 
of sample at each time point with an equal volume of PBS) and loss to the atmosphere. 
By the end of 6 hours, the concentration remaining is 66% of the starting concentration. 
Figure IV-7 shows that the experimental groups with microspheres in the solution 
variably improved the stability of the concentration. The 1 M GA, 25 mM loaded group 
had a higher concentration relative to its initial concentration compared to the control; 
this difference reached significance in the time period from 60 to 180 minutes. 
Thereafter, the fraction of the concentration remaining approaches that of the control. 
This trend matches our explanation that 1 M GA crosslinked microspheres release H2S 
near the beginning of the time-window, but not towards the end.  
In contrast, both 50 mM and 100 mM NaHS loaded, 4.75 M GA microspheres 
kept the H2S concentration higher than their respective initial concentrations. However, 
due to large variability in the data, the difference was significant only for 100 mM NaHS 




initial concentration stayed higher than the same ratio for the control group for all time-
points after 30 minutes, with the exception of the data point at t= 300 minutes. This 
observation also supports the trend towards continuous release of H2S apparent in the 
data for net amount released of H2S per milligram. 
The variation in the experiments is quite large. An underlying factor that 
confounds the trends is the difficulty in controlling the residual loading solution in the 
experimental tubes. As explained in the Methods, at the start of the experiment, the 
loading solution is removed from the microcentrifuge tube by a micropipetter. Fresh PBS 
is then added to the tube twice to wash the microspheres and remove residual loading 
solution. However, the procedure cannot guarantee the complete consistency in removing 
the residual loading solution. This factor affects the first measurement and all 
calculations of the net release thereafter. A more reliable means to measure H2S 
originating exclusively from microspheres (instead of residual loading solution), would 
improve the precision and accuracy of our results. 
The release experiments thus show that crosslinking density and loading 
concentration are parameters that can be changed to produce different types of release 
profiles. Future work can test intermediate or higher crosslinking concentrations to see 
what type of release profile results. The data suggests that microspheres with higher 
loading concentration and higher crosslinking density improve the stability of the bulk 
solution concentration. Thus, 4.75 M GA, 100 mM microspheres were selected for the 
subsequent studies to produce a cold-storage solution with relatively constant H2S levels, 
towards the preservation of rat hearts. 




H2S released from crosslinked microspheres is taken up by 
cardiomyocytes 
Cardiomyocytes were demonstrated to uptake H2S released from crosslinked, 
H2S-loaded microspheres into solution. The rate of decrease of H2S in solution is higher 
in the presence of cardiomyocytes (Figure IV-11 and Figure IV-12), indicating that the 
cells must be taking up H2S. For the release of H2S in purely cell media, the loss of H2S 
from solution over time can be attributed to the evolution of H2S as a gas, which escapes 
from solution. When cardiomyocytes are added to the media, the percentage decrease 
from initial H2S concentration increases, meaning there is an additional pathway of 
escape of H2S from the media into the cells.  
A mass effect of microspheres is also demonstrated with the percent decrease of 
H2S in solution. Increasing the mass of H2S-loaded microspheres added to solution 
results in a smaller percent decrease of H2S (Figure IV-11 and Figure IV-12) because 
there is a higher initial amount of H2S in solution. For the same seeding density of cells, 
the amount of H2S metabolized should be similar with varying masses of microspheres. It 
is reasonable to expect the percent decrease of H2S to be smaller with higher masses of 
microspheres. This experimental trend indicates a H2S uptake threshold limit by the cells.  
A review of current literature regarding the consumption of exogenous H2S 
correlates with the acquired results. In trout gills, it was demonstrated that H2S is 
metabolized in an oxygen-dependent manner as H2S diffuses through chemoreceptive 
neuroepithelial cells (Olson, Healy et al. 2008). Thus, H2S uptake is known to require 
oxygen and diffusion through the cellular membrane. Another study showed the existence 




consumption (Doeller, Isbell et al. 2005). In rat aorta smooth muscle cells, consumption 
rates are dependent on H2S concentration with saturation kinetics of a Km of less than 
5 M H2S and Vma of approximately 40 pmol s-1mg protein-1(Doeller, Isbell et al. 2005). 
These kinetics demonstrate a concentration range in which H2S is consumed by cells. For 
H2S concentrations less than 30 M, cellular consumption rates were about 10-fold 
greater than the spontaneous H2S oxidation rates found without the presence of 
enzymatically-active cells (Doeller, Isbell et al. 2005). Greater than 100 M H2S, the H2S 
consumption rate was comparable to the oxidation rate, showing that H2S consumption is 
inhibited at higher H2S levels (Doeller, Isbell et al. 2005). Although the primary enzymes 
for H2S consumption in animals still remain unknown, the study showed that these 
enzymes have an operating range of 0.5 to 50 M H2S, which is in line with the 
concentration of H2S in mammalian blood and tissues (Doeller, Isbell et al. 2005). 
In the context of these existing studies, the results showing uptake of H2S by the 
cardiomyocytes can be explained by the concentration-dependent consumption of H2S by 
cells. With the uptake mechanism of H2S via diffusion through the cellular membrane, 
there was a noticeable difference in rate of decrease of H2S from solution with varying 
masses of H2S-loaded microspheres. The lower rate of H2S depletion from solution with 
greater masses of microspheres (and thus higher concentration of released H2S) 
demonstrates that there is saturation kinetics involved in the consumption of H2S, as 
defined in the previously mentioned study. Thus, it is apparent that the cell has 






The MTT cytotoxicity test was chosen to determine the relative metabolic activity 
of a flat culture of cardiomyocytes due to its objectivity and ease of spectrophotometric 
measurement. It worked well for the NaHS-only incubation experiment. However, it 
could not be similarly utilized for experiments involving microspheres because the 
microspheres could not be entirely removed from the liquid; microspheres would have 
artificially increased spectrophotometric measures and would have yielded inflated 
measurements. The live/dead assay (also known as a viability assay) was chosen instead 
for relative viability experiments involving microspheres. As an intercalating agent, 
ethidium homodimer yielded a colorimetric response after penetrating the  cells with 
permeabilized membranes in the culture. Calcein AM was taken up by functioning cells 
and metabolized to yield a fluorescent green color in viable cells. This assay was 
quantified by taking pictures under a fluorescence microscope and counting the number 
of dead cells. The total number of cells was determined using an event counter on the 
program Image J (developed by NIH). The percent of live cells was then determined and 
was utilized to compare the effects of the drug delivery system on cardiomyocyte 
viability. 
 A small baseline of cell death was expected from the live/dead stain because the 
cells were incubated in their respective H2S treatments for one hour in a chemical fume 
hood at room temperature (25°C), not a biological hood.  Addition of fresh media was 
used to minimize cell death. After one hour incubation, the cells were washed and again 
incubated for a half-hour with the live/dead stain reagents, which could have caused 




Microspheres Alone have a Negative E ffect on Viability  
Microspheres were fabricated using non-toxic, biodegradable materials, so it is 
unlikely the baseline of cell death in this group could be attributed to the products of 
microsphere degradation or from the intact gelatin spheres themselves. The downward 
trend in cell survival in the icrosphere  group could be due to decreased oxygen 
delivery to cells residing under microspheres (Figure IV-8and Figure IV-9). The surface 
area of the non-circulating fluid was partially blocked by the microsphere mass, which 
most likely settled to the bottom of the wells. Therefore, a slight decrease in viability in a 
flat culture is expected. This problem is unlikely to occur in dynamic whole-heart 
conditions but may be expected in this system.  
  
The Cardioprotective E ffects of H2S 
The relative viabilities of the microsphere group were subtracted from the H2S-
loaded microsphere group to observe the sole effect of H2S on cell viability.  After 
accounting for the effect of the microspheres, the trends in viability are different. The 
NaHS-cultured groups demonstrated a slight increased ability to survive the culture 
period; percent of live cells increased by 0.1% for the 50mg group and by 2.6% for the 
250mg group Figure IV-9. However, the percent of viable cells decreased by 10.2% in 
the 100mg group. The 100mg group of microspheres alone had significantly more cell 
death than the 0 and 50mg groups, but not significantly more cell death than the 250mg 
group of microspheres alone. The NaHS-alone studies showed a general protective trend 
(decreased cell death) as concentration increased (Figure IV-8 and  




tested of amount of microspheres and releasing and cytoprotective ability. Possibly the 
250mg group represents the point at which the slight detrimental effect of microspheres 
was overpowered by the stronger protective effect of NaHS. When the groups are 
normalized to the 0mg group, the 50mg and the 250mg group demonstrate enhanced 
viability.  
Cardiomyocyte Viability is enhanced by H2S 
Mitochondria are an important focus because they both sustain and cause injury to 
cardiac tissue during ischemia and reperfusion. Controlling mitochondrial oxidative 
output may act to decrease heart tissue death. H2S acts by decreasing mitochondrial 
electron transport and is associated with cytochrome c retention and lower amounts of 
ROS (Chen, Camara et al. 2007). The metabolic activity assay was chosen for use in this 
study specifically to quantify metabolic recovery. Furthermore, metabolic function is 
correlated with cell survival. The metabolic activity assay therefore gives insight into 
both the cell viability and metabolic activity. 
The metabolic activity test results show a significant increase in cell metabolic 
activity as the amount of NaHS added to the media increases. Surprisingly, although the 
10,000uL group demonstrates higher viability than both the 0 and 1,000uL groups, 
respectively, it is not significantly higher than the 10uL group. To further investigate the 
effect of NaHS on cell metabolic activity, increasing amounts/concentrations of NaHS 
should be tested to find the threshold where adding more NaHS becomes toxic to the 
cells and decreases the cell metabolic activity. Learning this threshold will allow better 




This result should also be viewed in the context of H2
function. Inhalation of H2S caused a decrease of metabolic rate by 90% in murine 
subjects within 10 minutes. Mice were exposed to H2S for a total of 6 hours. Afterward, 
metabolic rate returned to baseline levels within an hour (Blackstone, Morrison et al. 
2005). In this study, cardiomyocytes were incubated for 1 hour with NaHS, and afterward 
were immediately incubated with the MTT reagent for 4 hours. Cardiomyocytes in the 
experimental groups therefore began the incubation period with suppressed metabolic 
function. The ability of the experimental groups to recover metabolic function and 
surpass the control group is more impressive when viewed from this context.  
 
Drug Delivery Implications 
Our results replicate the findings of prior studies, which conclude that H2S has 
significant cardioprotective effects. We further quantify this effect at levels of NaHS that 
are safe for clinical use and present a novel drug delivery vehicle for use in vivo. 
There is a threshold between the 50mg and 100mg groups where the effect of 
microspheres overrides the protective effects of H2S and causes increased cell apoptosis. 
The microspheres should be limited to less than 100mg per well in a 6-well plate because 
the cell viability trends downward beyond this point. Cell survival with NaHS trends 
upward with more NaHS enhancing the viability potential of cells. The limiting factor 
appears to be the total amount of NaHS that can be loaded into microspheres. To produce 
the highest protective effects, microspheres should be loaded with a maximum 




It appears that not only is our drug delivery system safe for use in vivo, but NaHS 
may confer additional protective effects at normothermic temperatures. Because each 
incubation period with NaHS, microspheres, and a combination of both was only one 
hour long, H2S did not have time to work over a long period of time. Incubation with the 
MTT reagents was four hours long, which is four times longer than the NaHS incubation 
period, and incubation with the live/dead reagents was a half-hour long. As previously 
suggested these prolonged incubation times outside an incubator and inside a chemical 
fume hood could lead to increased cell death. Thus this would artificially decrease the 
percent of viable cells. Further research with incubation periods greater than one hour 
with NaHS and microspheres could illuminate long-term protective abilities of the drug 
delivery system. Furthermore, neither interactions between NaHS incubation and 
temperature were not studied, nor was NaHS used in conjunction with UW solution. With 
the basic safety and efficacy established, these studies may now be completed. 
Controlled release of H2S ex vivo 
The heart is a unique organ in that its ability to contract is essential to its function. 
Thus, unlike cells in other organs, the maintenance of ATP levels during preservation is 
especially crucial to cardiomyocytes, which use ATP not only to maintain intracellular 
homeostasis, but also to maintain a functional contractile apparatus (Hegge, Southard et 
al. 2001). ATP content in stored hearts has been widely used as an indicator of heart 
tissue preservation and myocyte recovery (Peltz, He et al. 2005; Hu, Li et al. 2007; 
Zheng, Min et al. 2008). Here, we looked at ATP content as a representative measure of 
how well the heart might function following storage with NaHS both in solution and 




state of suspended animation, during which hypometabolic conditions can save energy 
through suppression of both ATP-consuming and ATP-generating processes (Storey 
2004; Hu, Li et al. 2007).  
ATP Content Changes Suggest Prolonged Preservation in the Presence of 
H2S 
The comparison between the UW control (C-UW) and experimental groups across 
time points suggest that NaHS can prolong heart viability in storage. In the C-UW group, 
the ATP content was significantly greater at 0 hours compared to 2, 4, and 8 hours into 
storage (F igure I V-13).  In comparison, all three experimental groups, in which hearts 
were stored in UW solution with NaHS (E-UW+NaHS), stored in UW solution with 
NaHS and injected with PBS-loaded microspheres (E-UW+ S), or stored in UW solution 
with NaHS and injected with H2S-loaded microspheres (E-UW+ S+H2S), showed a 
significantly greater ATP content in tissue samples at 2 hours into storage than at 4 and 8 
hours (F igure I V-14). These results suggest that while a significant portion of ATP was 
lost between 0 and 2 hours in hearts stored in UW solution alone, the significant drop in 
ATP content occurred following 2 hours of storage in all hearts that were stored in UW 
solution with NaHS. This comparison overall would indicate that the presence of NaHS 
ions prolonged ATP 
preservation, which is subsequently suggestive of prolonged heart preservation. Although 
the ATP content of the C-UW group seemed to be depleted before the 2 hour time point, 
this result is in line with previous research that has shown that organs lose 95% of their 
ATP content within 2-4 hours during cold storage (Stringham, Southard et al. 1992; 




tissue samples biopsied at 6 hours of storage would not be significantly different in any 
group. Although tissue samples of 0 hr time points from the experimental groups were 
not available for comparison with the C-UW 0 hour time point, it is still noteworthy that 
the significant drop in ATP content occurs at different times between the UW control 
hearts and hearts treated with NaHS. Additionally, statistical analyses between groups at 
each of the time points, discussed below, provide further support for the conclusion that 
NaHS in UW solution preserves ATP content of hearts in storage. 
Although overall, the decrease across time in ATP content was expected, an 
unexpected finding from our analysis was that, in the C-ischemia+UW group, only the 2 
hour time point was found to be significantly greater than the 8 hour time point (F igure 
I V-13). The reliability of the 2 hour time point may be questionable when considering 
that the one-way ANOVA only yielded p = 0.0496, which is extremely close to the 
threshold of p = 0.05 for significance. It is unlikely that ATP content would increase in 
the C-ischemia+UW group hearts, which were subjected to a storage protocol meant to 
encourage apoptosis. However, there has been some evidence that ischemic 
preconditioning could confer protective benefits to explanted hearts against ischemia-
reperfusion injury (Kandilci, Gumusel et al. 2006; Ghadhanfar and Juggi 2007). One 
study has shown that ATP steadily increases over a 6 hour reperfusion period in hearts 
that were subjected to 45 minutes of global ischemia (Freude, Masters et al. 2000). Thus, 
the increase in ATP content at 2 hours may reflect an actual effect from ischemic 
preconditioning. However, the increase in ATP content was likely not sustained because 
the C-ischemia+UW hearts were stored in static UW solution, compared to the 




there have been discrepancies in reports of functional recovery following global ischemic 
preconditioning to hypothermic cardioplegia (Ghadhanfar and Juggi 2007). Our results 
are more in line with previous research that showed preconditioning with alternating 
episodes of ischemia and reperfusion reduced starting levels of ATP in canine hearts, but 
slowed ATP depletion by decreasing ATP utilization such that ATP content was 
significantly greater than in controls up until 40 minutes of ischemia (Murry, Richard et 
al. 1990). Although reperfusion was not utilized in this present study, our findings present 
an interesting avenue for further research. 
Statistical Analyses of ATP Content 
Statistical analyses were performed between groups in order to determine whether 
NaHS and microsphere delivery of NaHS not only prolonged, but also enhanced 
cardioprotection during cold storage. The results show that among the control groups at 0 
hours, the ATP content of C-UW hearts was significantly greater than that of C-frozen 
and C-ischemia+UW groups (F igure I V-14). The difference between C-UW and C-
ischemia+UW groups was expected due to the clinical precedent of using UW as a 
preservation solution, which would suggest better ATP preservation, and the ischemic 
conditions that the C-ischemia+UW group was subjected to, which has been shown to 
produce ATP depletion at the onset of storage (Murry, Richard et al. 1990). However, the 
difference between the C-UW group and the C-frozen group, which was flash frozen 
immediately after explantation with the expectation of preserving the heart in its most 
viable state, was unexpected. These results might suggest that the storage protocol itself 




if true, this effect would be systematic and would therefore have little effect on 
comparisons between groups.  
More interestingly, the ATP content for tissue samples from the 2 hour time point, 
at which all six groups can be compared, suggest that the presence of NaHS in UW 
comparison test showed that both E-UW+ S and E-UW+NaHS hearts, which have in 
common submersion in UW solution with NaHS, but without H2S-loaded microspheres 
during storage, showed significantly greater ATP content than C-ischemia and C-UW 
hearts (F igure I V-14). In contrast, there were no significant differences in ATP content 
among C-ischemia+UW, C-UW, and E-UW+ S+H2S groups, or among E-UW+NaHS, 
E-UW+ S, and E-UW+ S+H2S groups. These results complement previous research that 
has found similar benefits for ATP conservation in rat hearts stored with 1 mol/L NaHS 
in a bicarbonate buffer, Krebs-Henseleit solution (Hu, Li et al. 2007). Our results indicate 
that NaHS in UW solution can enhance ATP preservation to greater levels than UW 
solution alone. However, no significant differences were found between the E-
UW+ S+H2S group and any other group at 2 hours (F igure I V-14). While significant 
differences were found between E-UW+NaHS, E-UW+ S, and C-ischemia+UW and C-
UW, the ATP content of E-UW+ S+H2S hearts lies in the middle of these two pairs and 
did not reach a significant difference. This result may suggest that the E-UW+ S+H2S 
group also experienced the preservative benefits of NaHS in UW solution, similar to E-
UW+NaHS and E-UW+ S groups, but that confounding conditions insignificantly 




indicate that the microspheres themselves do not have detrimental effects on the heart 
after injection.  
Overall, results from assaying ATP content suggest that NaHS in solution can 
prolong heart viability as measured by energy reserves, and also enhance the effects of 
UW solution in storage. These results are limited, however, in that significant differences 
are only seen at 0 and 2 hours of storage, and the differences are no longer significant at 4 
hours (F igure I V-14) or at 8 hours (F igure I V-14). Also, a major limitation is the small 
sample size. As only duplicate biological samples were taken, our experimental design  
may be insufficient to show the actual underlying differences. The inconsistency with the 
currently accepted clinical standard of 4-6 hours in UW solution is not supported by our 
data. A potential systematic decrease in ATP content during storage and experimentation 
might contribute to this discrepancy by rendering differences in ATP content between 
groups too small to reach statistical significance. There is, albeit statistically insignificant, 
a trend in which the E-UW+NaHS group displays slightly higher ATP content at 4 and 8 
hours. Further experimentation with more replicates might strengthen this trend. 
Additionally, future research may investigate different measures of energy content to 
provide a more complete picture of how microsphere-controlled delivery of H2S can 
enhance energy preservation for recovery of contractile function following reperfusion. 
Alternate measures of energy reserve could include glycogen content, or the ratio of 
adenosine nucleotides rather than just ATP, which research has shown might be less 
correlated to heart function than high phosphate potential in general (Freude, Masters et 




Activated caspase-3 is a marker of apoptosis 
Caspase-3 is a protease that is activated during the early stages of apoptosis, or 
programmed cell death. Activation of the caspase family of proteins is believed to be a 
major mechanism of cell death and has been studied extensively in the context of I/R 
injury (Murphy and Steenbergen 2008). Histological stains with specific antibodies are 
commonly used to detect caspase-3 activity and visualize apoptotic cells (Freude, Masters 
et al. 2000; Elrod, Calvert et al. 2007; Kafa, Uysal et al. 2010).  
Optimization of caspase-3 staining 
In this study, we started with a standard histological method that takes advantage 
-
diaminobenzidine (DAB). When oxidized, DAB produces a brown end product that can 
be visualized through light microscopy (Key 2006). The general staining protocol 
involves first binding the antigen of interest with a specific primary antibody, in this case, 
anti-active caspase-3 (BD Pharmingen, San Diego, CA). The primary antibody is then 
bound by a biotinylated secondary antibody. A streptavidin-HRP conjugate is applied 
next, in which the streptavidin molecule binds to the biotin of the secondary antibody. 
The final step in visualization is reacting the HRP with DAB, which will produce brown 
staining of the antigen of interest.  
As with any immunohistochemistry, the protocol must be optimized to match the 
specific tissues and antibodies being investigated. One particularly persistent issue 
encountered in our optimization process was high levels of non-specific staining. Such 
-specific binding of each 




at too high concentrations. Additionally, streptavidin can bind to endogenous biotin 
molecules, which are found in a wide variety of tissues. Finally, DAB, which reacts with 
HRP, can also react with endogenous peroxidases.  
To prevent such background staining, blocking and optimization steps must be 
performed. In this study, we investigated various permutations of staining protocols that 
included hydrogen peroxide (0.3  3%) to block endogenous peroxidase activity, 
streptavidin and biotin (10  15 g/mL each) to block endogenous biotin, 2% bovine 
serum albumin (BSA) to block non-specific staining due to hydrophobic interactions and 
normal goat serum (1.5  10% in 1xPBS) to block non-specific staining from the 
secondary antibody, which were goat anti-rabbit immunoglobulins (Key 2006). Each 
antibody was also titrated, or tested at a range of suggested dilutions, in order to optimize 
our protocol. Additionally, the fixation protocol to preserve tissue morphology must also 
be optimized since incomplete or over-fixation can interfere with antigen retrieval. 
Samples in this study were fixed in -20 C acetone for 10-20 minutes. However, the 
investigators were unable to produce negative stainings with the exclusion of the primary 
antibody, indicating a high level of background signal.  
Caspase-3 results discussion 
Due to unforeseen difficulties in staining optimization, the results from staining 
tissue samples from each control and experimental group are largely inconclusive. The C-
UW and E-UW+NaHS slides, upon preliminary examination, seem to indicate higher 
numbers of apoptotic cells due to the greater intensity of brown staining when imaged at 
the same light intensity as the other samples. However, these results are contrary to 




activity, in UW solution (Hegge, Southard et al. 2001) and in the presence of H2S (Elrod, 
Calvert et al. 2007). Variations in the density of the tissue may have contributed to the 
seeming variation in staining density. Alternately, the tissue sections may have degraded 
while in the -80 C freezer. Not only was there a freezer malfunction during the time of 
our experiments, but our slices were frozen directly after being sliced on the cryostat. 
Tissue quality and morphology may have been better preserved had the slices been fixed 
following sectioning and then stored in the freezer, rather than being fixed immediately 
before the staining procedure. Furthermore, a higher objective lens with greater 
resolution may be used to more closely examine the slices. Until additional protocol 
optimization and standardization can be performed, it is difficult to make conclusions 
about whether the injection of H2S-loaded microspheres conferred additional protective 
benefits to the heart in storage.  
Hematoxylin and Eosin staining reveals no significant differences 
Samples from each group were analyzed under an inverted light microscope and 
examined for the above mentioned markers of tissue damage. Although a few isolated 
sites of lymphocytic infiltration were found, they were scattered across the groups such 
that no one sample had a significantly greater number of inflammatory occurrences. 
Overall, the H&E stain revealed no significant differences in tissue damage across the 
control or experimental groups (Figure IV-16).  
Although these results might be interpreted to mean that neither the H2S nor the 
presence of microspheres caused tissue damage, there are several experimental 
limitations that must be taken into consideration. One of the most significant limitations 




to restrictions in time and resources. Subsequently, the effects of random error and 
variations between individual samples would be significantly exaggerated. One such 
individual difference is the actual tissue size. By basic principles of probability, it is more 
likely that a larger tissue section would have a greater absolute number of inflammation 
sites, even if the overall percentage of inflammation sites per unit of area. Furthermore, 
without both biological and technical replicates, the data is not reliable enough to make 
firm conclusions. Therefore, although these preliminary results appear promising, they 
must be confirmed by additional replications of this study. 
Future directions for tissue viability tests 
Previous studies indicate that caspase-3 histological stains are a viable method of 
quantifying apoptotic cells. Thus, with further optimization of our caspase-3 protocol, we 
may visualize and quantify apoptotic nuclei. Additionally, there are alternate histological 
assays that can be applied to measure indicators of cell damage. One histological assay 
commonly seen in the literature is the TUNEL assay, which labels fragmented DNA and 
indicates late stage apoptosis (Peltz, He et al. 2005; Yang, Wu et al. 2006; Hu, Li et al. 
2007). Hematoxylin and eosin (HE) staining is also a standard histological stain used in a 
wide variety of research contexts and tissue types. Although HE staining is not 
specifically intended to reveal apoptotic markers, it can be used to visualize tissue and 
cell morphology. The morphology can be subsequently analyzed for indications of cell 
damage. This method has been previously applied to analyze myocardial inflammation, 
and thus could similarly be used in this study to compare myocardial damage after 
storage in UW solution with or without NaHS, and with or without the injection of H2S-




protein can also be measured by Western blot, which allows quantification of protein 
levels from tissue homogenates as compared to histological visualization of caspase-3-
positive nuclei in tissue sections (Rinaldi, Gobbi et al. 2006; Jha, Calvert et al. 2008).  
Furthermore, there are other markers of cell damage besides apoptosis. Necrosis 
and autophagy have also been shown to play a role in myocardial infarctions (Murphy 
and Steenbergen 2008). Additionally, creatine kinase is a macromolecule released upon 
cell lesion, when membrane integrity is lost. Therefore, determination of creatine kinase 
levels, specifically the cardiac isoenzyme of creatine kinase, CK-MB, can mark 
myocardial injury and detect myocardial infarction. CK-MB is also significant for its role 
in energy processes, since it catalyzes the conversion of phosphocreatine to ADP (de 
Souza, Olivieri et al. 2000).  
Perhaps the most clinically relevant tests of viability are functional tests upon 
reperfusion. Functional parameters commonly measured to determine heart viability are 
left ventricular developed pressure (LVDP), arrhythmias, coronary flow, heart rate, 
inflow, and pulmonary artery perfusate oxygen concentration (Peltz, He et al. 2005; 
Zhang, Huang et al. 2007). These tests often require a Langendorff perfusion apparatus, 
which was not available during this study. Therefore, future experiments after obtaining 
the Langendorff apparatus could measure heart function after storage and thus provide a 
more comprehensive view of the potential preservative advantages of storage in UW 





We have successfully manufactured microspheres that will not block capillaries, 
and we have shown that these microspheres, when crosslinked using 4.75M 
glutaraldehyde solution and soaked overnight in 100mM NaHS, successfully sustain H2S 
concentrations. We found that while the upper limit to microspheres in a 6-well culture 
plate is 100mg, the H2S released by these microspheres is taken up by cardiomyocytes. In 
addition, when higher levels of H2S were introduced via the microspheres, protective 
effects increased. This suggests that the optimal configuration of microspheres is those 
with the highest H2S loading, but with the lowest mass of microspheres possible. Our 
results also show that at a minimum, the H2S delivery method developed here is 
comparable to current clinical preservation methods. 
Potential future directions include taking this work and performing functional 
assessments in a small mammal, such as the Langendorff perfusion apparatus, which 
assesses heart function ex vivo after preservation. Further biological assessments may 
also be conducted. Additionally, this work may be expanded to other organs, like the 
liver and kidneys. This work can also be expanded to other preservation techniques, like 
adding further compounds to improve preservation, or by adding microspheres and using 
continuous perfusion during the ex vivo period. Sustaining release of H2S has the 
potential to significantly expand ex vivo storage times and improve transplant outcomes. 
 Future directions can also include modifications to the microspheres. The gelatin 
backbone could be modified to have specific H2S affinity. Additionally, the aldehyde-




using sodium borohydride. Also, analyzing the perfusate would demonstrate if there are 
microspheres left in the heart and if continuous perfusion of H2S has any harmful effects 
to the heart. Microspheres can be examined after multiple reperfusions to determine if 
any changes occur between reperfusions. Further steps are required to implement this 
method in a clinical setting. Prior to patient exposure, the microspheres can be treated 








1 M vs. 4.75 M 
G A , 25 mM 
NaHS 
4.75 M G A , 25 
vs. 50 mM NaHS 
4.75 M G A , 25 
vs. 100 mM 
NaHS 
4.75 M G A , 50 
vs. 100 mM 
NaHS 
0.5 0.0893 0.2400 0.0297 0.1710 
15 0.0915 0.2389 0.0270 0.1108 
30 X 0.1780 0.0067 0.0227 
60 0.0697 0.0884 0.0015 0.0056 
120 0.0834 0.1292 0.0018 0.0487 
180 0.0530 0.0669 0.0007 0.0068 
240 0.0825 0.0850 0.0003 0.0262 
300 0.0463 0.0269 0.0003 0.0138 
360 0.0602 0.0409 0.0011 0.0234 
Table V I I-1: P-values from the ANOVA comparisons of the net H2S released per milligram microsphere 





Control vs. 1 M 
G A , 25 mM 
NaHS 
Control vs. 4.75 M 
G A , 25 mM NaHS 
Control vs. 4.75 
M G A , 100 mM 
NaHS 
1 M vs. 4.75 M 
G A , 25 mM 
NaHS 
15 0.1794 0.0337 0.2297 0.3144 
30 X 0.0688 0.0086 X 
60 0.0414 0.4143 0.0124 0.4001 
120 0.0231 0.1656 0.0497 0.7780 
180 0.0321 0.3135 0.0100 0.8377 
240 0.0645 0.1503 0.0261 0.7463 
300 0.1192 0.3529 0.0608 0.8554 
360 0.2536 0.4137 0.0236 0.7768 
Table V I I-2: P-values from the ANOVA comparisons of the bulk solution concentration from various 








T erm Definition 
Acidosis A condition in which there is excessive acid in a  body fluid 
Aerobic Metabolism Intracellular chemical reactions requiring oxygen in order for 
the organism to properly function 
Allograft A transplant that originates from a member of the same 
species as the transplant recipient. 
Anabolism Energy-requiring reactions that result in the synthesis of 
larger molecules from smaller units 
Anaerobic Metabolism A form of respiration using electron acceptors and 
instruments other than oxygen 
ANOVA ANalysis Of VAriance - statistical test that measures the 
means of several groups 
Antegrade Moving in a forward direction 
Anti-port An integral membrane protein that involved in secondary 
active transport of two or more different molecules or ions 
across a phospholipid membrane in opposite directions. 
Antioxidant A molecule capable of inhibiting the oxidation of other 
molecule 
Apoptosis Programmed cell death 




T erm Definition 
Assay A procedure for testing or measuring the activity of a drug or 
biochemical 
Atomizer A spray bottle with a nozzle for producing a fine spray  
ATP Adenosine  Triphosphate; the main source of energy to 
power metabolic processes in the cell 
Cardiomyocytes Involuntary, striated muscle cells found in the heart 
Cardioplegia Intentional and temporary cessation of cardiac activity, 
primarily for cardiac surgery 
Caspase An enzyme that plays an important role in apoptosis 
Catecholamines "Fight-or-flight" hormones released by the adrenal glands in 
response to stress (sympathetic nervous system response). 
Catecholamines include epinephrine and norepinephrine. 
Cell The functional basic unit of life 
Collagen A group of naturally occurring proteins that is the main 
component of connective tissue 
Colloid Substance dispersed evenly throughout another substance on 
a molecular level 
Concentration Strength of a solution; measure of how much of a given 
substance there is mixed with another substance 
Coronary Relating to the arteries that supply the heart tissues and 




T erm Definition 
Crosslinking The process of bonding that links one polymer chain to 
another by covalent bonds or ionic bonds. 
Cytokine A small cell-signaling molecule protein molecule used 
during intracellular communication 
Cytoprotective The quality of being protective to cells against harmful 
agents 
Defibrillation The action of delivering an electrical current to a heart in 
acute failure in order to reestablish normal sinus rhythm 
Density Mass per unit volume (e.g. g/mL) 
Diastole The period of time when the heart fills with blood after 
systole (contraction) 
DNA Deoxyribonucleic acid; contains the genetic instructions for 
the development and function of living organisms. 
Echocardiogram A sonogram of the heart to assess blood flow and cardiac 
valve function 
Edema Swelling caused by fluid retention in the body's tissues 
Electrocardiogram An external capture of the electrical activity of the heart 
measured using skin electrodes. A common diagnostic tool 
for abnormal rhythms of the heart or myocardial infarction. 
Electron Transport 
Chain 
Couples electron transfer between an electron donor (such as 
NADH) and an electron acceptor (such as O2) to the transfer 




T erm Definition 
ELISA Stands for Enzyme-linked immunosorbent assay. ELISA is a 
biochemical technique used mainly in immunology to detect 
the presence of an antibody or an antigen in a sample 
Endothelial Referring to the thin layer along the insides of blood vessels, 
separating blood from the vessel wall 
Enzyme A protein that increases the rate of a chemical reaction in 
living organisms 
Ex Vivo Outside the organism 
Explantation The removal of cells, tissues, or organs of animals and plants 
Fixation (tissue) A chemical process by which biological tissues are preserved 
from decay, either through autolysis or putrefaction 
Gasotransmitters Gaseous molecules synthesized in the body, such as 
hydrogen sulfide and nitric oxide 
Gelatin A solid substance, derived from the collagen inside animals' 
skin and bones; commonly used in food, pharmaceuticals, 
photography, and cosmetic manufacturing 
Glutaraldehyde An organic compound with the formula CH2(CH2CHO)2 
used for crosslinking gelatin into polymers 
Histology The study of the microscopic anatomy of cells and tissues of 
plants and animals 
Hydrogel A network of polymer chains that are hydrophilic, commonly 




T erm Definition 
Hydrogen sulfide (H2S) A colorless, very poisonous, flammable gas with the 
characteristic foul odor of rotten eggs that is endogenously 
produced in human body in small amounts as signaling 
molecules 
Hyperkalemic Elevated intracellular potassium levels 
Hypothermia A condition in which the body temperature falls below the 
necessary temperature for proper metabolism and body 
functions, usually around 35.0C 
In Situ to examine the phenomenon exactly in place where it occurs 
In Vitro When a procedure is performed in a controlled, non-living 
environment, such as in a test tube 
In Vivo When a procedure is performed in a living organism 
Infarction The process which causes an area of dead tissue due to a loss 
of blood supply 
Ion A charged atom or molecule 
Ischemia A restriction in blood supply leading to tissue death 
Ischemia/Reperfusion 
Injury 
Tissue damage caused when blood supply returns to the 
tissue after a period of ischemia 
Membrane A flexible enclosing or separating tissue forming a plane or 
film that separates two environments in a living organism 





T erm Definition 
Micron/Micrometer 10-6 meters 
Microspheres Small spherical particles with diameters in the micrometer  
range and manufactured from various natural and synthetic 
materials 
Mitochondria A membrane-enclosed organelle  found in most eukaryotic 
cells that is known as the "powerhouse" of the cell, as it 
produces ATP 
Molar A concentration, also called molarity, that measures of the 
concentration of a solute  in a solution in mols/L 
Morphology Relating to the form or structure of organisms and their 
specific structural features 
Myocardial infarction The interruption of blood supply to a part of the heart, 
causing heart cells to die; commonly known as heart attack 
Myocardium The middle of the three layers forming the wall of the heart 
NaHS Sodium hydrosulfide 
Necrosis The premature death of cells and living tissue 
Negative Control A control that confirms that the procedure is not observing an 
unrelated effect 
Normothermic To be at normal human body temperature 
Organ Care System A device by Transmedics that stores donor organs in a 




T erm Definition 
Osmolarity The measure of solute concentration in number of osmoles 
(Osm) of solute per liter (L) of solution  
Perfusate A fluid (as a solution pumped through the heart) that is 
circulated through blood vessels or other natural channels 
Plasma Component of blood 
Polymer A large molecule composed of repeating structural units 
Reperfusion When blood supply returns to the tissue after a period of 
ischemia 
Retrograde Moving in a direction contrary to the normal direction 
RNA Ribonucleic acid; catalyzes biological reactions, controls 
gene expression, synthesizes proteins 
ROS Radical oxidative species - chemically-reactive molecules 
containing oxygen such as oxygen ions and peroxides 
Sarcolemma The cell membrane of a muscle cell 
Spectrophotometer Machine that quantitatively measures the reflection or 
transmission properties of a material as a function of 
wavelength 
Spectroscopy The study of the interaction between matter and radiated 
energy 
St. Thomas Solution A preservation medium for use in organ transplantation 
Static Cold Storage The conventional method of preserving organs for 




T erm Definition 
Suspended animation A process in which biological activities are slowed down 
through external means without loss of life. Involuntary 
functions, breathing, and heart beating may still occur. 
Systole A phase of contraction during the cardiac cycle 
Transcapillary Through the capillary 
Transmembranal Through the cellular membrane 
Transplantation The moving of an organ from one body to another to replace 
the recipient's damaged or absent organ 
Troponin A complex of three regulatory proteins that is integral to 
muscle contraction in cardiac muscle 
Trypan Blue Exclusion 
Assay 
A visual dye test to determine cell viability. Dead cells 
stained a blue color can be distinguished from live cells 
under a microscope. 
TUNEL Terminal deoxynucleotidyl transferase; a method for 
detecting DNA fragmentation by labeling the terminal end of 
nucleic acids 
University of Wisconsin 
Solution 
the first intracellular-like preservation medium designed for 
use in organ transplantation; the current "gold standard" 
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